2-LTR circle formation
|
13 |
5-Phosphoribose 1-diphosphate biosynthesis
|
3 |
A tetrasaccharide linker sequence is required for GAG synthesis
|
26 |
ABC transporter disorders
|
76 |
ABC transporters in lipid homeostasis
|
18 |
ABC-family proteins mediated transport
|
103 |
ADP signalling through P2Y purinoceptor 1
|
25 |
ADP signalling through P2Y purinoceptor 12
|
22 |
AKT phosphorylates targets in the cytosol
|
14 |
AKT phosphorylates targets in the nucleus
|
10 |
AKT-mediated inactivation of FOXO1A
|
4 |
ALKBH2 mediated reversal of alkylation damage
|
1 |
ALKBH3 mediated reversal of alkylation damage
|
4 |
AMER1 mutants destabilize the destruction complex
|
14 |
AMPK inhibits chREBP transcriptional activation activity
|
8 |
APC truncation mutants are not K63 polyubiquitinated
|
1 |
APC truncation mutants have impaired AXIN binding
|
14 |
APC-Cdc20 mediated degradation of Nek2A
|
25 |
APC/C-mediated degradation of cell cycle proteins
|
86 |
APC/C:Cdc20 mediated degradation of Cyclin B
|
23 |
APC/C:Cdc20 mediated degradation of Securin
|
67 |
APC/C:Cdc20 mediated degradation of mitotic proteins
|
75 |
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
|
72 |
APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint
|
73 |
APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway
|
7 |
APOBEC3G mediated resistance to HIV-1 infection
|
12 |
ARL13B-mediated ciliary trafficking of INPP5E
|
3 |
ARMS-mediated activation
|
7 |
ATF4 activates genes
|
25 |
ATF6 (ATF6-alpha) activates chaperone genes
|
10 |
ATF6 (ATF6-alpha) activates chaperones
|
12 |
ATP sensitive Potassium channels
|
4 |
AUF1 (hnRNP D0) binds and destabilizes mRNA
|
56 |
AURKA Activation by TPX2
|
72 |
AXIN missense mutants destabilize the destruction complex
|
14 |
AXIN mutants destabilize the destruction complex, activating WNT signaling
|
14 |
Abacavir metabolism
|
5 |
Abacavir transmembrane transport
|
5 |
Abacavir transport and metabolism
|
10 |
Abasic sugar-phosphate removal via the single-nucleotide replacement pathway
|
2 |
Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate
|
1 |
Abortive elongation of HIV-1 transcript in the absence of Tat
|
23 |
Acetylation
|
2 |
Acetylcholine Neurotransmitter Release Cycle
|
17 |
Acetylcholine binding and downstream events
|
14 |
Acetylcholine regulates insulin secretion
|
10 |
Acrosome Reaction
|
1 |
Activated NOTCH1 Transmits Signal to the Nucleus
|
31 |
Activated NTRK2 signals through CDK5
|
6 |
Activated NTRK2 signals through FRS2 and FRS3
|
11 |
Activated NTRK2 signals through FYN
|
7 |
Activated NTRK2 signals through PI3K
|
7 |
Activated NTRK2 signals through PLCG1
|
4 |
Activated NTRK2 signals through RAS
|
10 |
Activated NTRK3 signals through PI3K
|
6 |
Activated NTRK3 signals through PLCG1
|
3 |
Activated NTRK3 signals through RAS
|
9 |
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
|
36 |
Activated point mutants of FGFR2
|
19 |
Activation and oligomerization of BAK protein
|
2 |
Activation of AKT2
|
4 |
Activation of AMPA receptors
|
4 |
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins
|
76 |
Activation of ATR in response to replication stress
|
37 |
Activation of BAD and translocation to mitochondria
|
15 |
Activation of BH3-only proteins
|
30 |
Activation of BIM and translocation to mitochondria
|
3 |
Activation of BMF and translocation to mitochondria
|
3 |
Activation of C3 and C5
|
7 |
Activation of Ca-permeable Kainate Receptor
|
10 |
Activation of CaMK IV
|
2 |
Activation of DNA fragmentation factor
|
13 |
Activation of E2F1 target genes at G1/S
|
28 |
Activation of G protein gated Potassium channels
|
25 |
Activation of GABAB receptors
|
39 |
Activation of HOX genes during differentiation
|
91 |
Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
|
17 |
Activation of Matrix Metalloproteinases
|
33 |
Activation of NF-kappaB in B cells
|
67 |
Activation of NIMA Kinases NEK9, NEK6, NEK7
|
7 |
Activation of NMDA receptor and postsynaptic events
|
39 |
Activation of NOXA and translocation to mitochondria
|
5 |
Activation of Na-permeable kainate receptors
|
2 |
Activation of Nicotinic Acetylcholine Receptors
|
14 |
Activation of PPARGC1A (PGC-1alpha) by phosphorylation
|
10 |
Activation of PUMA and translocation to mitochondria
|
9 |
Activation of RAC1
|
13 |
Activation of RAS in B cells
|
5 |
Activation of SMO
|
18 |
Activation of TRKA receptors
|
7 |
Activation of anterior HOX genes in hindbrain development during early embryogenesis
|
91 |
Activation of caspases through apoptosome-mediated cleavage
|
5 |
Activation of gene expression by SREBF (SREBP)
|
43 |
Activation of kainate receptors upon glutamate binding
|
30 |
Activation of the AP-1 family of transcription factors
|
10 |
Activation of the TFAP2 (AP-2) family of transcription factors
|
12 |
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S
|
60 |
Activation of the phototransduction cascade
|
11 |
Activation of the pre-replicative complex
|
33 |
Activation, myristolyation of BID and translocation to mitochondria
|
4 |
Activation, translocation and oligomerization of BAX
|
2 |
Acyl chain remodeling of CL
|
6 |
Acyl chain remodeling of DAG and TAG
|
8 |
Acyl chain remodelling of PC
|
27 |
Acyl chain remodelling of PE
|
29 |
Acyl chain remodelling of PG
|
18 |
Acyl chain remodelling of PI
|
17 |
Acyl chain remodelling of PS
|
22 |
Adaptive Immune System
|
944 |
Adenosine P1 receptors
|
4 |
Adenylate cyclase activating pathway
|
10 |
Adenylate cyclase inhibitory pathway
|
14 |
Adherens junctions interactions
|
33 |
Adrenaline signalling through Alpha-2 adrenergic receptor
|
3 |
Adrenaline,noradrenaline inhibits insulin secretion
|
28 |
Adrenoceptors
|
9 |
Advanced glycosylation endproduct receptor signaling
|
13 |
Aflatoxin activation and detoxification
|
20 |
Agmatine biosynthesis
|
2 |
Alpha-defensins
|
10 |
Alpha-oxidation of phytanate
|
6 |
Alternative complement activation
|
5 |
Amine Oxidase reactions
|
4 |
Amine ligand-binding receptors
|
43 |
Amine-derived hormones
|
18 |
Amino Acid conjugation
|
9 |
Amino acid synthesis and interconversion (transamination)
|
35 |
Amino acid transport across the plasma membrane
|
34 |
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
|
94 |
Amplification of signal from the kinetochores
|
94 |
Amyloid fiber formation
|
71 |
Anchoring fibril formation
|
15 |
Anchoring of the basal body to the plasma membrane
|
97 |
Androgen biosynthesis
|
11 |
Antagonism of Activin by Follistatin
|
4 |
Antigen Presentation: Folding, assembly and peptide loading of class I MHC
|
93 |
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
100 |
Antigen processing-Cross presentation
|
168 |
Antigen processing: Ubiquitination & Proteasome degradation
|
309 |
Antimicrobial peptides
|
95 |
Antiviral mechanism by IFN-stimulated genes
|
78 |
Apoptosis
|
171 |
Apoptosis induced DNA fragmentation
|
13 |
Apoptotic cleavage of cell adhesion proteins
|
11 |
Apoptotic cleavage of cellular proteins
|
38 |
Apoptotic execution phase
|
52 |
Apoptotic factor-mediated response
|
7 |
Aquaporin-mediated transport
|
53 |
Arachidonate production from DAG
|
5 |
Arachidonic acid metabolism
|
59 |
Aromatic amines can be N-hydroxylated or N-dealkylated by CYP1A2
|
1 |
Aryl hydrocarbon receptor signalling
|
7 |
Asparagine N-linked glycosylation
|
304 |
Assembly Of The HIV Virion
|
24 |
Assembly of Viral Components at the Budding Site
|
7 |
Assembly of active LPL and LIPC lipase complexes
|
19 |
Assembly of collagen fibrils and other multimeric structures
|
61 |
Assembly of the ORC complex at the origin of replication
|
6 |
Assembly of the pre-replicative complex
|
68 |
Association of TriC/CCT with target proteins during biosynthesis
|
39 |
Astrocytic Glutamate-Glutamine Uptake And Metabolism
|
4 |
Asymmetric localization of PCP proteins
|
64 |
Attachment of GPI anchor to uPAR
|
7 |
Attenuation phase
|
14 |
Autodegradation of Cdh1 by Cdh1:APC/C
|
63 |
Autodegradation of the E3 ubiquitin ligase COP1
|
52 |
Autointegration results in viral DNA circles
|
9 |
Axon guidance
|
556 |
Axonal growth inhibition (RHOA activation)
|
9 |
Axonal growth stimulation
|
4 |
B-WICH complex positively regulates rRNA expression
|
60 |
BBSome-mediated cargo-targeting to cilium
|
23 |
BDNF activates NTRK2 (TRKB) signaling
|
2 |
BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
|
9 |
BMAL1:CLOCK,NPAS2 activates circadian gene expression
|
27 |
Base Excision Repair
|
39 |
Base-Excision Repair, AP Site Formation
|
11 |
Basigin interactions
|
25 |
Beta defensins
|
39 |
Beta oxidation of butanoyl-CoA to acetyl-CoA
|
5 |
Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA
|
6 |
Beta oxidation of hexanoyl-CoA to butanoyl-CoA
|
5 |
Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA
|
5 |
Beta oxidation of myristoyl-CoA to lauroyl-CoA
|
3 |
Beta oxidation of octanoyl-CoA to hexanoyl-CoA
|
5 |
Beta oxidation of palmitoyl-CoA to myristoyl-CoA
|
3 |
Beta-catenin independent WNT signaling
|
143 |
Beta-catenin phosphorylation cascade
|
17 |
Beta-oxidation of pristanoyl-CoA
|
9 |
Beta-oxidation of very long chain fatty acids
|
11 |
Bicarbonate transporters
|
10 |
Bile acid and bile salt metabolism
|
43 |
Binding and Uptake of Ligands by Scavenger Receptors
|
129 |
Binding and entry of HIV virion
|
12 |
Binding of TCF/LEF:CTNNB1 to target gene promoters
|
8 |
Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB
|
2 |
Biological oxidations
|
223 |
Biosynthesis of A2E, implicated in retinal degradation
|
1 |
Biosynthesis of D-series resolvins
|
4 |
Biosynthesis of DHA-derived SPMs
|
17 |
Biosynthesis of DHA-derived sulfido conjugates
|
2 |
Biosynthesis of DPA-derived SPMs
|
4 |
Biosynthesis of DPAn-3 SPMs
|
4 |
Biosynthesis of DPAn-3-derived 13-series resolvins
|
1 |
Biosynthesis of DPAn-3-derived maresins
|
2 |
Biosynthesis of DPAn-3-derived protectins and resolvins
|
2 |
Biosynthesis of DPAn-6 SPMs
|
2 |
Biosynthesis of E-series 18(R)-resolvins
|
4 |
Biosynthesis of E-series 18(S)-resolvins
|
5 |
Biosynthesis of EPA-derived SPMs
|
6 |
Biosynthesis of aspirin-triggered D-series resolvins
|
3 |
Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives
|
2 |
Biosynthesis of maresin conjugates in tissue regeneration (MCTR)
|
2 |
Biosynthesis of maresin-like SPMs
|
6 |
Biosynthesis of maresins
|
8 |
Biosynthesis of protectin and resolvin conjugates in tissue regeneration (PCTR and RCTR)
|
1 |
Biosynthesis of protectins
|
4 |
Biosynthesis of specialized proresolving mediators (SPMs)
|
19 |
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
|
78 |
Biotin transport and metabolism
|
11 |
Branched-chain amino acid catabolism
|
23 |
Breakdown of the nuclear lamina
|
3 |
Budding
|
9 |
Budding and maturation of HIV virion
|
36 |
Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA
|
17 |
Butyrophilin (BTN) family interactions
|
12 |
C-type lectin receptors (CLRs)
|
173 |
C6 deamination of adenosine
|
2 |
CASP8 activity is inhibited
|
14 |
CD209 (DC-SIGN) signaling
|
21 |
CD22 mediated BCR regulation
|
70 |
CD28 co-stimulation
|
33 |
CD28 dependent PI3K/Akt signaling
|
22 |
CD28 dependent Vav1 pathway
|
12 |
CDC6 association with the ORC:origin complex
|
11 |
CDK-mediated phosphorylation and removal of Cdc6
|
72 |
CDO in myogenesis
|
29 |
CDT1 association with the CDC6:ORC:origin complex
|
59 |
CHL1 interactions
|
9 |
CLEC7A (Dectin-1) induces NFAT activation
|
11 |
CLEC7A (Dectin-1) signaling
|
98 |
CLEC7A/inflammasome pathway
|
6 |
COPI-dependent Golgi-to-ER retrograde traffic
|
102 |
COPI-independent Golgi-to-ER retrograde traffic
|
52 |
COPI-mediated anterograde transport
|
101 |
COPII-mediated vesicle transport
|
68 |
COX reactions
|
1 |
CREB phosphorylation
|
7 |
CREB phosphorylation through the activation of Adenylate Cyclase
|
7 |
CREB phosphorylation through the activation of CaMKII
|
15 |
CREB phosphorylation through the activation of CaMKK
|
4 |
CREB phosphorylation through the activation of Ras
|
27 |
CREB3 factors activate genes
|
9 |
CRMPs in Sema3A signaling
|
16 |
CS/DS degradation
|
14 |
CTLA4 inhibitory signaling
|
21 |
CYP2E1 reactions
|
11 |
Ca-dependent events
|
28 |
Ca2+ activated K+ channels
|
9 |
Ca2+ pathway
|
59 |
CaM pathway
|
26 |
CaMK IV-mediated phosphorylation of CREB
|
3 |
Calcineurin activates NFAT
|
9 |
Calcitonin-like ligand receptors
|
11 |
Calmodulin induced events
|
26 |
Calnexin/calreticulin cycle
|
26 |
Cam-PDE 1 activation
|
4 |
Cap-dependent Translation Initiation
|
120 |
Carboxyterminal post-translational modifications of tubulin
|
42 |
Cardiac conduction
|
140 |
Cargo concentration in the ER
|
33 |
Cargo recognition for clathrin-mediated endocytosis
|
99 |
Cargo trafficking to the periciliary membrane
|
51 |
Carnitine synthesis
|
4 |
Caspase activation via extrinsic apoptotic signalling pathway
|
29 |
Caspase-mediated cleavage of cytoskeletal proteins
|
12 |
Catecholamine biosynthesis
|
4 |
Cation-coupled Chloride cotransporters
|
7 |
Cdc20:Phospho-APC/C mediated degradation of Cyclin A
|
72 |
Cell Cycle
|
621 |
Cell Cycle Checkpoints
|
274 |
Cell Cycle, Mitotic
|
514 |
Cell death signalling via NRAGE, NRIF and NADE
|
76 |
Cell junction organization
|
92 |
Cell redox homeostasis
|
9 |
Cell surface interactions at the vascular wall
|
245 |
Cell-Cell communication
|
130 |
Cell-cell junction organization
|
65 |
Cell-extracellular matrix interactions
|
18 |
Cellular Senescence
|
164 |
Cellular hexose transport
|
21 |
Cellular response to heat stress
|
93 |
Cellular response to hypoxia
|
75 |
Cellular responses to external stimuli
|
482 |
Cellular responses to stress
|
405 |
Centrosome maturation
|
81 |
Ceramide signalling
|
3 |
ChREBP activates metabolic gene expression
|
8 |
Chaperonin-mediated protein folding
|
95 |
Chemokine receptors bind chemokines
|
48 |
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
|
13 |
Cholesterol biosynthesis
|
26 |
Cholesterol biosynthesis via desmosterol
|
4 |
Cholesterol biosynthesis via lathosterol
|
4 |
Choline catabolism
|
6 |
Chondroitin sulfate biosynthesis
|
20 |
Chondroitin sulfate/dermatan sulfate metabolism
|
50 |
Chromatin modifying enzymes
|
241 |
Chromatin organization
|
241 |
Chromosome Maintenance
|
90 |
Chylomicron assembly
|
10 |
Chylomicron clearance
|
5 |
Chylomicron remodeling
|
10 |
Cilium Assembly
|
201 |
Circadian Clock
|
68 |
Citric acid cycle (TCA cycle)
|
22 |
Class A/1 (Rhodopsin-like receptors)
|
324 |
Class B/2 (Secretin family receptors)
|
97 |
Class C/3 (Metabotropic glutamate/pheromone receptors)
|
40 |
Class I MHC mediated antigen processing & presentation
|
440 |
Classical Kir channels
|
4 |
Classical antibody-mediated complement activation
|
95 |
Clathrin derived vesicle budding
|
74 |
Clathrin-mediated endocytosis
|
139 |
Clearance of Nuclear Envelope Membranes from Chromatin
|
10 |
Cleavage of Growing Transcript in the Termination Region
|
66 |
Cleavage of the damaged purine
|
4 |
Cleavage of the damaged pyrimidine
|
8 |
Cobalamin (Cbl, vitamin B12) transport and metabolism
|
21 |
Coenzyme A biosynthesis
|
8 |
Cohesin Loading onto Chromatin
|
10 |
Collagen biosynthesis and modifying enzymes
|
67 |
Collagen chain trimerization
|
44 |
Collagen degradation
|
64 |
Collagen formation
|
90 |
Common Pathway of Fibrin Clot Formation
|
22 |
Competing endogenous RNAs (ceRNAs) regulate PTEN translation
|
8 |
Complement cascade
|
146 |
Complex I biogenesis
|
55 |
Condensation of Prometaphase Chromosomes
|
11 |
Condensation of Prophase Chromosomes
|
45 |
Conjugation of benzoate with glycine
|
6 |
Conjugation of carboxylic acids
|
9 |
Conjugation of phenylacetate with glutamine
|
2 |
Conjugation of salicylate with glycine
|
8 |
Constitutive Signaling by AKT1 E17K in Cancer
|
26 |
Constitutive Signaling by Aberrant PI3K in Cancer
|
79 |
Constitutive Signaling by EGFRvIII
|
15 |
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
|
19 |
Constitutive Signaling by NOTCH1 HD Domain Mutants
|
15 |
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
|
59 |
Constitutive Signaling by NOTCH1 PEST Domain Mutants
|
59 |
Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
|
7 |
Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase
|
19 |
Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding
|
42 |
Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding
|
32 |
Costimulation by the CD28 family
|
88 |
Creatine metabolism
|
10 |
Creation of C4 and C2 activators
|
103 |
Cristae formation
|
31 |
Cross-presentation of particulate exogenous antigens (phagosomes)
|
8 |
Cross-presentation of soluble exogenous antigens (endosomes)
|
50 |
Crosslinking of collagen fibrils
|
18 |
Cyclin A/B1/B2 associated events during G2/M transition
|
25 |
Cyclin A:Cdk2-associated events at S phase entry
|
85 |
Cyclin D associated events in G1
|
44 |
Cyclin E associated events during G1/S transition
|
83 |
Cysteine formation from homocysteine
|
2 |
Cytochrome P450 - arranged by substrate type
|
65 |
Cytochrome c-mediated apoptotic response
|
5 |
Cytokine Signaling in Immune system
|
771 |
Cytosolic iron-sulfur cluster assembly
|
13 |
Cytosolic sensors of pathogen-associated DNA
|
63 |
Cytosolic sulfonation of small molecules
|
25 |
Cytosolic tRNA aminoacylation
|
24 |
DAG and IP3 signaling
|
32 |
DAP12 interactions
|
46 |
DAP12 signaling
|
29 |
DARPP-32 events
|
24 |
DCC mediated attractive signaling
|
14 |
DDX58/IFIH1-mediated induction of interferon-alpha/beta
|
77 |
DEx/H-box helicases activate type I IFN and inflammatory cytokines production
|
7 |
DNA Damage Bypass
|
49 |
DNA Damage Recognition in GG-NER
|
38 |
DNA Damage Reversal
|
8 |
DNA Damage/Telomere Stress Induced Senescence
|
61 |
DNA Double Strand Break Response
|
60 |
DNA Double-Strand Break Repair
|
148 |
DNA Repair
|
296 |
DNA Replication
|
127 |
DNA Replication Pre-Initiation
|
85 |
DNA methylation
|
34 |
DNA replication initiation
|
8 |
DNA strand elongation
|
32 |
DSCAM interactions
|
11 |
Deactivation of the beta-catenin transactivating complex
|
42 |
Deadenylation of mRNA
|
25 |
Deadenylation-dependent mRNA decay
|
56 |
Death Receptor Signalling
|
147 |
Dectin-1 mediated noncanonical NF-kB signaling
|
60 |
Dectin-2 family
|
61 |
Defective ABCA1 causes Tangier disease
|
1 |
Defective ABCA12 causes autosomal recessive congenital ichthyosis type 4B
|
1 |
Defective ABCA3 causes pulmonary surfactant metabolism dysfunction 3 (SMDP3)
|
1 |
Defective ABCA3 causes pulmonary surfactant metabolism dysfunction type 3 (SMDP3)
|
1 |
Defective ABCB11 causes progressive familial intrahepatic cholestasis 2 and benign recurrent intrahepatic cholestasis 2
|
1 |
Defective ABCB4 causes progressive familial intrahepatic cholestasis 3, intrahepatic cholestasis of pregnancy 3 and gallbladder disease 1
|
1 |
Defective ABCB6 causes isolated colobomatous microphthalmia 7 (MCOPCB7)
|
1 |
Defective ABCC2 causes Dubin-Johnson syndrome
|
1 |
Defective ABCC6 causes pseudoxanthoma elasticum (PXE)
|
1 |
Defective ABCC8 can cause hypoglycemias and hyperglycemias
|
2 |
Defective ABCC9 causes dilated cardiomyopathy 10, familial atrial fibrillation 12 and hypertrichotic osteochondrodysplasia
|
1 |
Defective ABCD1 causes adrenoleukodystrophy (ALD)
|
1 |
Defective ABCD4 causes methylmalonic aciduria and homocystinuria, cblj type (MAHCJ)
|
1 |
Defective ABCG5 causes sitosterolemia
|
2 |
Defective ABCG8 causes gallbladder disease 4 and sitosterolemia
|
2 |
Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
|
2 |
Defective ACY1 causes encephalopathy
|
1 |
Defective AHCY causes Hypermethioninemia with S-adenosylhomocysteine hydrolase deficiency (HMAHCHD)
|
1 |
Defective ALG1 causes ALG1-CDG (CDG-1k)
|
1 |
Defective ALG11 causes ALG11-CDG (CDG-1p)
|
1 |
Defective ALG12 causes ALG12-CDG (CDG-1g)
|
1 |
Defective ALG14 causes congenital myasthenic syndrome (ALG14-CMS)
|
2 |
Defective ALG2 causes ALG2-CDG (CDG-1i)
|
1 |
Defective ALG3 causes ALG3-CDG (CDG-1d)
|
1 |
Defective ALG6 causes ALG6-CDG (CDG-1c)
|
1 |
Defective ALG8 causes ALG8-CDG (CDG-1h)
|
1 |
Defective ALG9 causes ALG9-CDG (CDG-1l)
|
1 |
Defective AMN causes hereditary megaloblastic anemia 1
|
3 |
Defective AVP causes neurohypophyseal diabetes insipidus (NDI)
|
2 |
Defective AVP causes neurohypophyseal diabetes insipidus (NDI)
|
3 |
Defective B3GALT6 causes EDSP2 and SEMDJL1
|
20 |
Defective B3GALTL causes Peters-plus syndrome (PpS)
|
38 |
Defective B3GAT3 causes JDSSDHD
|
20 |
Defective B4GALT1 causes B4GALT1-CDG (CDG-2d)
|
8 |
Defective B4GALT1 causes B4GALT1-CDG (CDG-2d)
|
1 |
Defective B4GALT7 causes EDS, progeroid type
|
20 |
Defective BTD causes biotidinase deficiency
|
1 |
Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS)
|
19 |
Defective CD320 causes methylmalonic aciduria
|
2 |
Defective CFTR causes cystic fibrosis
|
61 |
Defective CHST14 causes EDS, musculocontractural type
|
8 |
Defective CHST3 causes SEDCJD
|
8 |
Defective CHST6 causes MCDC1
|
8 |
Defective CHSY1 causes TPBS
|
8 |
Defective CP causes aceruloplasminemia (ACERULOP)
|
1 |
Defective CSF2RA causes pulmonary surfactant metabolism dysfunction 4 (SMDP4)
|
8 |
Defective CSF2RB causes pulmonary surfactant metabolism dysfunction 5 (SMDP5)
|
8 |
Defective CUBN causes hereditary megaloblastic anemia 1
|
3 |
Defective CYP11A1 causes Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR)
|
4 |
Defective CYP11B1 causes Adrenal hyperplasia 4 (AH4)
|
1 |
Defective CYP11B2 causes Corticosterone methyloxidase 1 deficiency (CMO-1 deficiency)
|
1 |
Defective CYP17A1 causes Adrenal hyperplasia 5 (AH5)
|
1 |
Defective CYP19A1 causes Aromatase excess syndrome (AEXS)
|
1 |
Defective CYP1B1 causes Glaucoma
|
1 |
Defective CYP21A2 causes Adrenal hyperplasia 3 (AH3)
|
1 |
Defective CYP24A1 causes Hypercalcemia, infantile (HCAI)
|
1 |
Defective CYP26B1 causes Radiohumeral fusions with other skeletal and craniofacial anomalies (RHFCA)
|
1 |
Defective CYP26C1 causes Focal facial dermal dysplasia 4 (FFDD4)
|
1 |
Defective CYP27A1 causes Cerebrotendinous xanthomatosis (CTX)
|
1 |
Defective CYP27B1 causes Rickets vitamin D-dependent 1A (VDDR1A)
|
1 |
Defective CYP2R1 causes Rickets vitamin D-dependent 1B (VDDR1B)
|
1 |
Defective CYP2U1 causes Spastic paraplegia 56, autosomal recessive (SPG56)
|
1 |
Defective CYP4F22 causes Ichthyosis, congenital, autosomal recessive 5 (ARCI5)
|
1 |
Defective CYP7B1 causes Spastic paraplegia 5A, autosomal recessive (SPG5A) and Congenital bile acid synthesis defect 3 (CBAS3)
|
1 |
Defective DHDDS causes retinitis pigmentosa 59
|
1 |
Defective DOLK causes DOLK-CDG (CDG-1m)
|
1 |
Defective DPAGT1 causes DPAGT1-CDG (CDG-1j) and CMSTA2
|
1 |
Defective DPM1 causes DPM1-CDG (CDG-1e)
|
1 |
Defective DPM2 causes DPM2-CDG (CDG-1u)
|
1 |
Defective DPM3 causes DPM3-CDG (CDG-1o)
|
1 |
Defective EXT1 causes exostoses 1, TRPS2 and CHDS
|
14 |
Defective EXT2 causes exostoses 2
|
14 |
Defective FMO3 causes Trimethylaminuria (TMAU)
|
1 |
Defective GALE can cause Epimerase-deficiency galactosemia (EDG)
|
1 |
Defective GALK1 can cause Galactosemia II (GALCT2)
|
1 |
Defective GALNT12 causes colorectal cancer 1 (CRCS1)
|
19 |
Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC)
|
19 |
Defective GALT can cause Galactosemia
|
1 |
Defective GCK causes maturity-onset diabetes of the young 2 (MODY2)
|
1 |
Defective GCLC causes Hemolytic anemia due to gamma-glutamylcysteine synthetase deficiency (HAGGSD)
|
1 |
Defective GFPT1 causes CMSTA1
|
1 |
Defective GGT1 causes Glutathionuria (GLUTH)
|
1 |
Defective GGT1 causes Glutathionuria (GLUTH)
|
1 |
Defective GIF causes intrinsic factor deficiency
|
1 |
Defective GNE causes sialuria, Nonaka myopathy and inclusion body myopathy 2
|
1 |
Defective GSS causes Glutathione synthetase deficiency (GSS deficiency)
|
1 |
Defective HEXA causes GM2G1
|
1 |
Defective HEXB causes GM2G2
|
1 |
Defective HK1 causes hexokinase deficiency (HK deficiency)
|
1 |
Defective HLCS causes multiple carboxylase deficiency
|
7 |
Defective LARGE causes MDDGA6 and MDDGB6
|
1 |
Defective LFNG causes SCDO3
|
5 |
Defective LMBRD1 causes methylmalonic aciduria and homocystinuria type cblF
|
1 |
Defective MAN1B1 causes MRT15
|
1 |
Defective MAOA causes Brunner syndrome (BRUNS)
|
1 |
Defective MAT1A causes Methionine adenosyltransferase deficiency (MATD)
|
1 |
Defective MGAT2 causes MGAT2-CDG (CDG-2a)
|
1 |
Defective MMAA causes methylmalonic aciduria type cblA
|
2 |
Defective MMAB causes methylmalonic aciduria type cblB
|
1 |
Defective MMACHC causes methylmalonic aciduria and homocystinuria type cblC
|
1 |
Defective MMADHC causes methylmalonic aciduria and homocystinuria type cblD
|
2 |
Defective MOGS causes MOGS-CDG (CDG-2b)
|
1 |
Defective MPDU1 causes MPDU1-CDG (CDG-1f)
|
1 |
Defective MPI causes MPI-CDG (CDG-1b)
|
1 |
Defective MTR causes methylmalonic aciduria and homocystinuria type cblG
|
2 |
Defective MTRR causes methylmalonic aciduria and homocystinuria type cblE
|
2 |
Defective MUT causes methylmalonic aciduria mut type
|
2 |
Defective Mismatch Repair Associated With MLH1
|
2 |
Defective Mismatch Repair Associated With MSH2
|
3 |
Defective Mismatch Repair Associated With MSH3
|
2 |
Defective Mismatch Repair Associated With MSH6
|
2 |
Defective Mismatch Repair Associated With PMS2
|
2 |
Defective NEU1 causes sialidosis
|
1 |
Defective OPLAH causes 5-oxoprolinase deficiency (OPLAHD)
|
1 |
Defective PAPSS2 causes SEMD-PA
|
1 |
Defective PGM1 causes PGM1-CDG (CDG1t)
|
1 |
Defective PMM2 causes PMM2-CDG (CDG-1a)
|
1 |
Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3
|
2 |
Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1
|
2 |
Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2
|
2 |
Defective RFT1 causes RFT1-CDG (CDG-1n)
|
1 |
Defective RHAG causes regulator type Rh-null hemolytic anemia (RHN)
|
1 |
Defective SFTPA2 causes idiopathic pulmonary fibrosis (IPF)
|
2 |
Defective SLC11A2 causes hypochromic microcytic anemia, with iron overload 1 (AHMIO1)
|
1 |
Defective SLC12A1 causes Bartter syndrome 1 (BS1)
|
1 |
Defective SLC12A3 causes Gitelman syndrome (GS)
|
1 |
Defective SLC12A6 causes agenesis of the corpus callosum, with peripheral neuropathy (ACCPN)
|
1 |
Defective SLC16A1 causes symptomatic deficiency in lactate transport (SDLT)
|
1 |
Defective SLC17A5 causes Salla disease (SD) and ISSD
|
1 |
Defective SLC17A8 causes autosomal dominant deafness 25 (DFNA25)
|
1 |
Defective SLC1A1 is implicated in schizophrenia 18 (SCZD18) and dicarboxylic aminoaciduria (DCBXA)
|
1 |
Defective SLC1A3 causes episodic ataxia 6 (EA6)
|
1 |
Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1)
|
1 |
Defective SLC22A12 causes renal hypouricemia 1 (RHUC1)
|
1 |
Defective SLC22A18 causes lung cancer (LNCR) and embryonal rhabdomyosarcoma 1 (RMSE1)
|
1 |
Defective SLC22A5 causes systemic primary carnitine deficiency (CDSP)
|
1 |
Defective SLC24A1 causes congenital stationary night blindness 1D (CSNB1D)
|
1 |
Defective SLC24A4 causes hypomineralized amelogenesis imperfecta (AI)
|
1 |
Defective SLC24A5 causes oculocutaneous albinism 6 (OCA6)
|
1 |
Defective SLC26A2 causes chondrodysplasias
|
1 |
Defective SLC26A3 causes congenital secretory chloride diarrhea 1 (DIAR1)
|
1 |
Defective SLC26A4 causes Pendred syndrome (PDS)
|
1 |
Defective SLC27A4 causes ichthyosis prematurity syndrome (IPS)
|
1 |
Defective SLC29A3 causes histiocytosis-lymphadenopathy plus syndrome (HLAS)
|
1 |
Defective SLC2A1 causes GLUT1 deficiency syndrome 1 (GLUT1DS1)
|
1 |
Defective SLC2A10 causes arterial tortuosity syndrome (ATS)
|
1 |
Defective SLC2A2 causes Fanconi-Bickel syndrome (FBS)
|
1 |
Defective SLC2A9 causes hypouricemia renal 2 (RHUC2)
|
1 |
Defective SLC33A1 causes spastic paraplegia 42 (SPG42)
|
1 |
Defective SLC34A1 causes hypophosphatemic nephrolithiasis/osteoporosis 1 (NPHLOP1)
|
1 |
Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM)
|
1 |
Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM)
|
1 |
Defective SLC34A3 causes Hereditary hypophosphatemic rickets with hypercalciuria (HHRH)
|
1 |
Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F)
|
1 |
Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F)
|
1 |
Defective SLC35A2 causes congenital disorder of glycosylation 2M (CDG2M)
|
1 |
Defective SLC35A3 causes arthrogryposis, mental retardation, and seizures (AMRS)
|
1 |
Defective SLC35C1 causes congenital disorder of glycosylation 2C (CDG2C)
|
1 |
Defective SLC35D1 causes Schneckenbecken dysplasia (SCHBCKD)
|
1 |
Defective SLC36A2 causes iminoglycinuria (IG) and hyperglycinuria (HG)
|
1 |
Defective SLC39A4 causes acrodermatitis enteropathica, zinc-deficiency type (AEZ)
|
1 |
Defective SLC3A1 causes cystinuria (CSNU)
|
1 |
Defective SLC40A1 causes hemochromatosis 4 (HFE4) (duodenum)
|
1 |
Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages)
|
1 |
Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4), distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)
|
1 |
Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA)
|
1 |
Defective SLC5A1 causes congenital glucose/galactose malabsorption (GGM)
|
1 |
Defective SLC5A2 causes renal glucosuria (GLYS1)
|
1 |
Defective SLC5A5 causes thyroid dyshormonogenesis 1 (TDH1)
|
1 |
Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A)
|
1 |
Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A)
|
1 |
Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria
|
1 |
Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria
|
1 |
Defective SLC6A19 causes Hartnup disorder (HND)
|
1 |
Defective SLC6A19 causes Hartnup disorder (HND)
|
1 |
Defective SLC6A2 causes orthostatic intolerance (OI)
|
1 |
Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS)
|
1 |
Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS)
|
1 |
Defective SLC6A5 causes hyperekplexia 3 (HKPX3)
|
1 |
Defective SLC7A7 causes lysinuric protein intolerance (LPI)
|
1 |
Defective SLC7A9 causes cystinuria (CSNU)
|
1 |
Defective SLC9A6 causes X-linked, syndromic mental retardation,, Christianson type (MRXSCH)
|
1 |
Defective SLC9A9 causes autism 16 (AUTS16)
|
1 |
Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)
|
1 |
Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)
|
2 |
Defective SLCO1B3 causes hyperbilirubinemia, Rotor type (HBLRR)
|
2 |
Defective SLCO2A1 causes primary, autosomal recessive hypertrophic osteoarthropathy 2 (PHOAR2)
|
1 |
Defective SRD5A3 causes SRD5A3-CDG (CDG-1q) and KHRZ
|
1 |
Defective ST3GAL3 causes MCT12 and EIEE15
|
8 |
Defective TBXAS1 causes Ghosal hematodiaphyseal dysplasia (GHDD)
|
1 |
Defective TCN2 causes hereditary megaloblastic anemia
|
1 |
Defective TPMT causes Thiopurine S-methyltransferase deficiency (TPMT deficiency)
|
1 |
Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC)
|
3 |
Defective UGT1A1 causes hyperbilirubinemia
|
1 |
Defective UGT1A4 causes hyperbilirubinemia
|
1 |
Defective pro-SFTPB causes pulmonary surfactant metabolism dysfunction 1 (SMDP1) and respiratory distress syndrome (RDS)
|
3 |
Defective pro-SFTPC causes pulmonary surfactant metabolism dysfunction 2 (SMDP2) and respiratory distress syndrome (RDS)
|
2 |
Defects in biotin (Btn) metabolism
|
8 |
Defects in cobalamin (B12) metabolism
|
14 |
Defects in vitamin and cofactor metabolism
|
22 |
Defensins
|
49 |
Degradation of AXIN
|
55 |
Degradation of DVL
|
57 |
Degradation of GABA
|
2 |
Degradation of GLI1 by the proteasome
|
60 |
Degradation of GLI2 by the proteasome
|
60 |
Degradation of beta-catenin by the destruction complex
|
82 |
Degradation of cysteine and homocysteine
|
14 |
Degradation of the extracellular matrix
|
140 |
Depolymerisation of the Nuclear Lamina
|
16 |
Deposition of new CENPA-containing nucleosomes at the centromere
|
54 |
Depurination
|
4 |
Depyrimidination
|
8 |
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
|
23 |
Dermatan sulfate biosynthesis
|
11 |
Detoxification of Reactive Oxygen Species
|
39 |
Deubiquitination
|
282 |
Developmental Biology
|
1053 |
Digestion
|
22 |
Digestion and absorption
|
27 |
Digestion of dietary carbohydrate
|
10 |
Digestion of dietary lipid
|
7 |
Dimerization of procaspase-8
|
11 |
Disassembly of the destruction complex and recruitment of AXIN to the membrane
|
31 |
Disease
|
1148 |
Diseases associated with N-glycosylation of proteins
|
17 |
Diseases associated with O-glycosylation of proteins
|
69 |
Diseases associated with glycosaminoglycan metabolism
|
41 |
Diseases associated with glycosylation precursor biosynthesis
|
15 |
Diseases associated with surfactant metabolism
|
12 |
Diseases associated with the TLR signaling cascade
|
26 |
Diseases associated with visual transduction
|
13 |
Diseases of Immune System
|
26 |
Diseases of Mismatch Repair (MMR)
|
5 |
Diseases of carbohydrate metabolism
|
34 |
Diseases of glycosylation
|
141 |
Diseases of metabolism
|
105 |
Diseases of signal transduction
|
392 |
Disinhibition of SNARE formation
|
5 |
Disorders of transmembrane transporters
|
144 |
Displacement of DNA glycosylase by APEX1
|
10 |
Dissolution of Fibrin Clot
|
13 |
Dopamine Neurotransmitter Release Cycle
|
23 |
Dopamine clearance from the synaptic cleft
|
4 |
Dopamine receptors
|
5 |
Downregulation of ERBB2 signaling
|
32 |
Downregulation of ERBB2:ERBB3 signaling
|
14 |
Downregulation of ERBB4 signaling
|
10 |
Downregulation of SMAD2/3:SMAD4 transcriptional activity
|
23 |
Downregulation of TGF-beta receptor signaling
|
26 |
Downstream TCR signaling
|
116 |
Downstream signal transduction
|
30 |
Downstream signaling events of B Cell Receptor (BCR)
|
81 |
Downstream signaling of activated FGFR1
|
34 |
Downstream signaling of activated FGFR2
|
34 |
Downstream signaling of activated FGFR3
|
27 |
Downstream signaling of activated FGFR4
|
28 |
Dual Incision in GG-NER
|
41 |
Dual incision in TC-NER
|
65 |
E2F mediated regulation of DNA replication
|
22 |
E2F-enabled inhibition of pre-replication complex formation
|
9 |
E3 ubiquitin ligases ubiquitinate target proteins
|
59 |
ECM proteoglycans
|
76 |
EGFR Transactivation by Gastrin
|
9 |
EGFR downregulation
|
25 |
EGFR interacts with phospholipase C-gamma
|
3 |
EPH-Ephrin signaling
|
92 |
EPH-ephrin mediated repulsion of cells
|
51 |
EPHA-mediated growth cone collapse
|
29 |
EPHB-mediated forward signaling
|
42 |
ER Quality Control Compartment (ERQC)
|
21 |
ER to Golgi Anterograde Transport
|
154 |
ER-Phagosome pathway
|
152 |
ERBB2 Activates PTK6 Signaling
|
16 |
ERBB2 Regulates Cell Motility
|
18 |
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression
|
45 |
ERK/MAPK targets
|
22 |
ERKs are inactivated
|
13 |
ESR-mediated signaling
|
126 |
Early Phase of HIV Life Cycle
|
22 |
Effects of PIP2 hydrolysis
|
27 |
Eicosanoid ligand-binding receptors
|
15 |
Eicosanoids
|
12 |
Elastic fibre formation
|
45 |
Electric Transmission Across Gap Junctions
|
5 |
Electron transport from NADPH to Ferredoxin
|
3 |
Elevation of cytosolic Ca2+ levels
|
16 |
Endogenous sterols
|
27 |
Endosomal Sorting Complex Required For Transport (ESCRT)
|
31 |
Endosomal/Vacuolar pathway
|
79 |
Energy dependent regulation of mTOR by LKB1-AMPK
|
29 |
Entry of Influenza Virion into Host Cell via Endocytosis
|
11 |
Enzymatic degradation of Dopamine by monoamine oxidase
|
2 |
Enzymatic degradation of dopamine by COMT
|
3 |
Ephrin signaling
|
19 |
Epigenetic regulation of gene expression
|
117 |
Erythrocytes take up carbon dioxide and release oxygen
|
12 |
Erythrocytes take up oxygen and release carbon dioxide
|
8 |
Essential fructosuria
|
1 |
Essential pentosuria
|
1 |
Establishment of Sister Chromatid Cohesion
|
11 |
Estrogen biosynthesis
|
6 |
Estrogen-dependent gene expression
|
120 |
Ethanol oxidation
|
12 |
Eukaryotic Translation Elongation
|
95 |
Eukaryotic Translation Initiation
|
120 |
Eukaryotic Translation Termination
|
94 |
Export of Viral Ribonucleoproteins from Nucleus
|
41 |
Expression and Processing of Neurotrophins
|
4 |
Extension of Telomeres
|
30 |
Extracellular matrix organization
|
301 |
Extrinsic Pathway of Fibrin Clot Formation
|
5 |
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis
|
55 |
FBXW7 Mutants and NOTCH1 in Cancer
|
6 |
FCERI mediated Ca+2 mobilization
|
117 |
FCERI mediated MAPK activation
|
118 |
FCERI mediated NF-kB activation
|
167 |
FCGR activation
|
101 |
FGFR1 ligand binding and activation
|
18 |
FGFR1 mutant receptor activation
|
33 |
FGFR1b ligand binding and activation
|
6 |
FGFR1c and Klotho ligand binding and activation
|
4 |
FGFR1c ligand binding and activation
|
12 |
FGFR2 alternative splicing
|
26 |
FGFR2 ligand binding and activation
|
23 |
FGFR2 mutant receptor activation
|
38 |
FGFR2b ligand binding and activation
|
11 |
FGFR2c ligand binding and activation
|
14 |
FGFR3 ligand binding and activation
|
14 |
FGFR3 mutant receptor activation
|
14 |
FGFR3b ligand binding and activation
|
7 |
FGFR3c ligand binding and activation
|
13 |
FGFR4 ligand binding and activation
|
14 |
FGFR4 mutant receptor activation
|
1 |
FGFRL1 modulation of FGFR1 signaling
|
13 |
FMO oxidises nucleophiles
|
3 |
FRS-mediated FGFR1 signaling
|
25 |
FRS-mediated FGFR2 signaling
|
28 |
FRS-mediated FGFR3 signaling
|
21 |
FRS-mediated FGFR4 signaling
|
22 |
Factors involved in megakaryocyte development and platelet production
|
159 |
Fanconi Anemia Pathway
|
38 |
FasL/ CD95L signaling
|
5 |
Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion
|
8 |
Fatty acid metabolism
|
179 |
Fatty acids
|
15 |
Fatty acyl-CoA biosynthesis
|
37 |
Fc epsilon receptor (FCERI) signaling
|
217 |
Fcgamma receptor (FCGR) dependent phagocytosis
|
175 |
Fertilization
|
26 |
Fibronectin matrix formation
|
6 |
Ficolins bind to repetitive carbohydrate structures on the target cell surface
|
5 |
Folding of actin by CCT/TriC
|
10 |
Formation of ATP by chemiosmotic coupling
|
18 |
Formation of Fibrin Clot (Clotting Cascade)
|
39 |
Formation of HIV elongation complex in the absence of HIV Tat
|
48 |
Formation of HIV-1 elongation complex containing HIV-1 Tat
|
47 |
Formation of Incision Complex in GG-NER
|
43 |
Formation of RNA Pol II elongation complex
|
61 |
Formation of Senescence-Associated Heterochromatin Foci (SAHF)
|
16 |
Formation of TC-NER Pre-Incision Complex
|
53 |
Formation of a pool of free 40S subunits
|
102 |
Formation of annular gap junctions
|
11 |
Formation of apoptosome
|
3 |
Formation of editosomes by ADAR proteins
|
2 |
Formation of the Early Elongation Complex
|
33 |
Formation of the Editosome
|
8 |
Formation of the HIV-1 Early Elongation Complex
|
33 |
Formation of the active cofactor, UDP-glucuronate
|
3 |
Formation of the beta-catenin:TCF transactivating complex
|
60 |
Formation of the cornified envelope
|
129 |
Formation of the ternary complex, and subsequently, the 43S complex
|
52 |
Formation of tubulin folding intermediates by CCT/TriC
|
25 |
Formation of xylulose-5-phosphate
|
5 |
Formyl peptide receptors bind formyl peptides and many other ligands
|
9 |
Free fatty acid receptors
|
5 |
Free fatty acids regulate insulin secretion
|
8 |
Frs2-mediated activation
|
10 |
Fructose biosynthesis
|
2 |
Fructose catabolism
|
5 |
Fructose metabolism
|
7 |
Fusion and Uncoating of the Influenza Virion
|
9 |
Fusion of the Influenza Virion to the Host Cell Endosome
|
9 |
G alpha (12/13) signalling events
|
87 |
G alpha (i) signalling events
|
397 |
G alpha (q) signalling events
|
212 |
G alpha (s) signalling events
|
577 |
G alpha (z) signalling events
|
48 |
G beta:gamma signalling through PI3Kgamma
|
25 |
G beta:gamma signalling through PLC beta
|
20 |
G protein gated Potassium channels
|
25 |
G-protein activation
|
28 |
G-protein beta:gamma signalling
|
28 |
G-protein mediated events
|
45 |
G0 and Early G1
|
27 |
G1 Phase
|
44 |
G1/S DNA Damage Checkpoints
|
68 |
G1/S Transition
|
131 |
G1/S-Specific Transcription
|
28 |
G2 Phase
|
5 |
G2/M Checkpoints
|
151 |
G2/M DNA damage checkpoint
|
78 |
G2/M DNA replication checkpoint
|
5 |
G2/M Transition
|
197 |
GAB1 signalosome
|
11 |
GABA A (rho) receptor activation
|
3 |
GABA A receptor activation
|
13 |
GABA B receptor activation
|
39 |
GABA receptor activation
|
55 |
GABA synthesis
|
2 |
GABA synthesis, release, reuptake and degradation
|
19 |
GDP-fucose biosynthesis
|
6 |
GLI proteins bind promoters of Hh responsive genes to promote transcription
|
3 |
GLI3 is processed to GLI3R by the proteasome
|
60 |
GP1b-IX-V activation signalling
|
12 |
GPCR downstream signalling
|
1146 |
GPCR ligand binding
|
461 |
GPVI-mediated activation cascade
|
35 |
GRB2 events in EGFR signaling
|
7 |
GRB2 events in ERBB2 signaling
|
18 |
GRB2:SOS provides linkage to MAPK signaling for Integrins
|
15 |
GRB7 events in ERBB2 signaling
|
6 |
GTP hydrolysis and joining of the 60S ribosomal subunit
|
113 |
Galactose catabolism
|
6 |
Gamma carboxylation, hypusine formation and arylsulfatase activation
|
39 |
Gamma-carboxylation of protein precursors
|
10 |
Gamma-carboxylation, transport, and amino-terminal cleavage of proteins
|
11 |
Gap junction assembly
|
37 |
Gap junction degradation
|
12 |
Gap junction trafficking
|
48 |
Gap junction trafficking and regulation
|
50 |
Gap-filling DNA repair synthesis and ligation in GG-NER
|
25 |
Gap-filling DNA repair synthesis and ligation in TC-NER
|
64 |
Gastrin-CREB signalling pathway via PKC and MAPK
|
18 |
Gene Silencing by RNA
|
108 |
Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
|
38 |
Gene expression (Transcription)
|
1416 |
Generation of second messenger molecules
|
52 |
Generic Transcription Pathway
|
1152 |
Global Genome Nucleotide Excision Repair (GG-NER)
|
84 |
Glucagon signaling in metabolic regulation
|
34 |
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
|
43 |
Glucagon-type ligand receptors
|
34 |
Glucocorticoid biosynthesis
|
9 |
Gluconeogenesis
|
34 |
Glucose metabolism
|
96 |
Glucuronidation
|
24 |
Glutamate Neurotransmitter Release Cycle
|
24 |
Glutamate binding, activation of AMPA receptors and synaptic plasticity
|
31 |
Glutathione conjugation
|
37 |
Glutathione synthesis and recycling
|
13 |
Glycerophospholipid biosynthesis
|
129 |
Glycerophospholipid catabolism
|
7 |
Glycine degradation
|
4 |
Glycogen breakdown (glycogenolysis)
|
16 |
Glycogen metabolism
|
27 |
Glycogen storage disease type 0 (liver GYS2)
|
2 |
Glycogen storage disease type 0 (muscle GYS1)
|
2 |
Glycogen storage disease type II (GAA)
|
2 |
Glycogen storage disease type IV (GBE1)
|
3 |
Glycogen storage disease type Ia (G6PC)
|
1 |
Glycogen storage disease type Ib (SLC37A4)
|
1 |
Glycogen storage disease type XV (GYG1)
|
2 |
Glycogen storage diseases
|
16 |
Glycogen synthesis
|
16 |
Glycolysis
|
76 |
Glycoprotein hormones
|
10 |
Glycosaminoglycan metabolism
|
124 |
Glycosphingolipid metabolism
|
46 |
Glyoxylate metabolism and glycine degradation
|
31 |
Golgi Associated Vesicle Biogenesis
|
56 |
Golgi Cisternae Pericentriolar Stack Reorganization
|
14 |
Golgi-to-ER retrograde transport
|
136 |
Growth hormone receptor signaling
|
24 |
HATs acetylate histones
|
108 |
HCN channels
|
4 |
HDACs deacetylate histones
|
60 |
HDL assembly
|
8 |
HDL clearance
|
5 |
HDL remodeling
|
11 |
HDMs demethylate histones
|
27 |
HDR through Homologous Recombination (HRR)
|
66 |
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA)
|
114 |
HDR through MMEJ (alt-NHEJ)
|
10 |
HDR through Single Strand Annealing (SSA)
|
37 |
HHAT G278V abrogates palmitoylation of Hh-Np
|
4 |
HIV Infection
|
246 |
HIV Life Cycle
|
163 |
HIV Transcription Elongation
|
47 |
HIV Transcription Initiation
|
47 |
HIV elongation arrest and recovery
|
36 |
HS-GAG biosynthesis
|
31 |
HS-GAG degradation
|
22 |
HSF1 activation
|
12 |
HSF1-dependent transactivation
|
24 |
HSP90 chaperone cycle for steroid hormone receptors (SHR)
|
56 |
Hedgehog 'off' state
|
113 |
Hedgehog 'on' state
|
85 |
Hedgehog ligand biogenesis
|
65 |
Heme biosynthesis
|
11 |
Heme degradation
|
6 |
Hemostasis
|
723 |
Heparan sulfate/heparin (HS-GAG) metabolism
|
55 |
Hereditary fructose intolerance
|
1 |
Hh mutants abrogate ligand secretion
|
59 |
Hh mutants that don't undergo autocatalytic processing are degraded by ERAD
|
56 |
Highly calcium permeable nicotinic acetylcholine receptors
|
9 |
Highly calcium permeable postsynaptic nicotinic acetylcholine receptors
|
11 |
Highly sodium permeable acetylcholine nicotinic receptors
|
7 |
Histamine receptors
|
4 |
Histidine catabolism
|
8 |
Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism
|
46 |
Homologous DNA Pairing and Strand Exchange
|
42 |
Homology Directed Repair
|
120 |
Hormone ligand-binding receptors
|
13 |
Host Interactions of HIV factors
|
142 |
Host Interactions with Influenza Factors
|
48 |
HuR (ELAVL1) binds and stabilizes mRNA
|
8 |
Hyaluronan biosynthesis and export
|
5 |
Hyaluronan metabolism
|
17 |
Hyaluronan uptake and degradation
|
12 |
Hydrolysis of LPC
|
9 |
Hydrolysis of LPE
|
2 |
Hydroxycarboxylic acid-binding receptors
|
3 |
Hypusine synthesis from eIF5A-lysine
|
4 |
IGF1R signaling cascade
|
61 |
IKBKB deficiency causes SCID
|
3 |
IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
|
3 |
IKK complex recruitment mediated by RIP1
|
23 |
IL-6-type cytokine receptor ligand interactions
|
17 |
IRAK1 recruits IKK complex
|
14 |
IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
|
14 |
IRAK2 mediated activation of TAK1 complex
|
10 |
IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation
|
16 |
IRAK4 deficiency (TLR2/4)
|
12 |
IRAK4 deficiency (TLR5)
|
5 |
IRE1alpha activates chaperones
|
57 |
IRF3 mediated activation of type 1 IFN
|
5 |
IRF3-mediated induction of type I IFN
|
13 |
IRS activation
|
5 |
IRS-mediated signalling
|
54 |
IRS-related events triggered by IGF1R
|
58 |
ISG15 antiviral mechanism
|
78 |
IkBA variant leads to EDA-ID
|
7 |
Immune System
|
2226 |
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
|
297 |
Import of palmitoyl-CoA into the mitochondrial matrix
|
14 |
Inactivation of APC/C via direct inhibition of the APC/C complex
|
20 |
Inactivation of CDC42 and RAC1
|
8 |
Inactivation, recovery and regulation of the phototransduction cascade
|
33 |
Incretin synthesis, secretion, and inactivation
|
23 |
Infectious disease
|
460 |
Inflammasomes
|
24 |
Influenza Infection
|
169 |
Influenza Life Cycle
|
158 |
Influenza Viral RNA Transcription and Replication
|
149 |
Influenza Virus Induced Apoptosis
|
4 |
Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits
|
25 |
Inhibition of Host mRNA Processing and RNA Silencing
|
3 |
Inhibition of IFN-beta
|
1 |
Inhibition of Interferon Synthesis
|
1 |
Inhibition of PKR
|
2 |
Inhibition of Signaling by Overexpressed EGFR
|
2 |
Inhibition of TSC complex formation by PKB
|
3 |
Inhibition of adenylate cyclase pathway
|
14 |
Inhibition of replication initiation of damaged DNA by RB1/E2F1
|
13 |
Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components
|
20 |
Initial triggering of complement
|
111 |
Initiation of Nuclear Envelope Reformation
|
14 |
InlA-mediated entry of Listeria monocytogenes into host cells
|
10 |
InlB-mediated entry of Listeria monocytogenes into host cell
|
16 |
Innate Immune System
|
1180 |
Inositol phosphate metabolism
|
48 |
Inositol transporters
|
3 |
Insulin effects increased synthesis of Xylulose-5-Phosphate
|
2 |
Insulin processing
|
27 |
Insulin receptor recycling
|
26 |
Insulin receptor signalling cascade
|
60 |
Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA
|
3 |
Integration of energy metabolism
|
111 |
Integration of provirus
|
15 |
Integration of viral DNA into host genomic DNA
|
9 |
Integrin alphaIIb beta3 signaling
|
28 |
Integrin cell surface interactions
|
85 |
Integrin signaling
|
28 |
Interaction With Cumulus Cells
|
1 |
Interaction With The Zona Pellucida
|
10 |
Interaction between L1 and Ankyrins
|
31 |
Interaction between PHLDA1 and AURKA
|
2 |
Interactions of Rev with host cellular proteins
|
40 |
Interactions of Tat with host cellular proteins
|
3 |
Interactions of Vpr with host cellular proteins
|
45 |
Interconversion of 2-oxoglutarate and 2-hydroxyglutarate
|
3 |
Interconversion of nucleotide di- and triphosphates
|
30 |
Interconversion of polyamines
|
3 |
Interferon Signaling
|
284 |
Interferon alpha/beta signaling
|
137 |
Interferon gamma signaling
|
172 |
Interleukin receptor SHC signaling
|
27 |
Interleukin-1 family signaling
|
140 |
Interleukin-1 processing
|
7 |
Interleukin-1 signaling
|
102 |
Interleukin-10 signaling
|
45 |
Interleukin-12 family signaling
|
57 |
Interleukin-12 signaling
|
47 |
Interleukin-15 signaling
|
14 |
Interleukin-17 signaling
|
71 |
Interleukin-18 signaling
|
9 |
Interleukin-2 family signaling
|
45 |
Interleukin-2 signaling
|
12 |
Interleukin-20 family signaling
|
25 |
Interleukin-21 signaling
|
10 |
Interleukin-23 signaling
|
9 |
Interleukin-27 signaling
|
11 |
Interleukin-3, Interleukin-5 and GM-CSF signaling
|
48 |
Interleukin-33 signaling
|
4 |
Interleukin-35 Signalling
|
12 |
Interleukin-36 pathway
|
7 |
Interleukin-37 signaling
|
21 |
Interleukin-38 signaling
|
4 |
Interleukin-4 and Interleukin-13 signaling
|
111 |
Interleukin-6 family signaling
|
28 |
Interleukin-6 signaling
|
15 |
Interleukin-7 signaling
|
25 |
Interleukin-9 signaling
|
9 |
Intestinal absorption
|
5 |
Intestinal hexose absorption
|
4 |
Intestinal infectious diseases
|
3 |
Intestinal lipid absorption
|
1 |
Intestinal saccharidase deficiencies
|
2 |
Intra-Golgi and retrograde Golgi-to-ER traffic
|
205 |
Intra-Golgi traffic
|
44 |
Intracellular oxygen transport
|
3 |
Intracellular signaling by second messengers
|
300 |
Intraflagellar transport
|
53 |
Intrinsic Pathway for Apoptosis
|
44 |
Intrinsic Pathway of Fibrin Clot Formation
|
22 |
Invadopodia formation
|
4 |
Inwardly rectifying K+ channels
|
31 |
Ion channel transport
|
184 |
Ion homeostasis
|
54 |
Ion influx/efflux at host-pathogen interface
|
4 |
Ion transport by P-type ATPases
|
55 |
Ionotropic activity of kainate receptors
|
10 |
Iron uptake and transport
|
58 |
JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
|
22 |
Josephin domain DUBs
|
12 |
KSRP (KHSRP) binds and destabilizes mRNA
|
17 |
Keratan sulfate biosynthesis
|
28 |
Keratan sulfate degradation
|
13 |
Keratan sulfate/keratin metabolism
|
34 |
Keratinization
|
217 |
Ketone body metabolism
|
10 |
Kinesins
|
63 |
L13a-mediated translational silencing of Ceruloplasmin expression
|
112 |
L1CAM interactions
|
120 |
LDL clearance
|
19 |
LDL remodeling
|
4 |
LGI-ADAM interactions
|
14 |
LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
|
5 |
Lactose synthesis
|
3 |
Lagging Strand Synthesis
|
20 |
Laminin interactions
|
30 |
Late Phase of HIV Life Cycle
|
150 |
Latent infection of Homo sapiens with Mycobacterium tuberculosis
|
35 |
Leading Strand Synthesis
|
14 |
Lectin pathway of complement activation
|
8 |
Leukotriene receptors
|
5 |
Ligand-receptor interactions
|
8 |
Linoleic acid (LA) metabolism
|
8 |
Lipid particle organization
|
6 |
Listeria monocytogenes entry into host cells
|
22 |
Localization of the PINCH-ILK-PARVIN complex to focal adhesions
|
4 |
Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling
|
6 |
Loss of Function of SMAD2/3 in Cancer
|
7 |
Loss of Function of SMAD4 in Cancer
|
3 |
Loss of Function of TGFBR1 in Cancer
|
7 |
Loss of Function of TGFBR2 in Cancer
|
4 |
Loss of Nlp from mitotic centrosomes
|
69 |
Loss of proteins required for interphase microtubule organization from the centrosome
|
69 |
Lysine catabolism
|
12 |
Lysosomal oligosaccharide catabolism
|
4 |
Lysosome Vesicle Biogenesis
|
37 |
Lysosphingolipid and LPA receptors
|
14 |
M Phase
|
370 |
M/G1 Transition
|
85 |
MAP kinase activation
|
63 |
MAP2K and MAPK activation
|
40 |
MAP3K8 (TPL2)-dependent MAPK1/3 activation
|
16 |
MAPK family signaling cascades
|
302 |
MAPK targets/ Nuclear events mediated by MAP kinases
|
31 |
MAPK1 (ERK2) activation
|
10 |
MAPK1/MAPK3 signaling
|
263 |
MAPK3 (ERK1) activation
|
11 |
MAPK6/MAPK4 signaling
|
89 |
MASTL Facilitates Mitotic Progression
|
10 |
MET Receptor Activation
|
6 |
MET activates PI3K/AKT signaling
|
6 |
MET activates PTK2 signaling
|
30 |
MET activates PTPN11
|
5 |
MET activates RAP1 and RAC1
|
11 |
MET activates RAS signaling
|
11 |
MET activates STAT3
|
3 |
MET interacts with TNS proteins
|
5 |
MET promotes cell motility
|
41 |
MET receptor recycling
|
10 |
MGMT-mediated DNA damage reversal
|
1 |
MHC class II antigen presentation
|
141 |
MPS I - Hurler syndrome
|
1 |
MPS II - Hunter syndrome
|
1 |
MPS IIIA - Sanfilippo syndrome A
|
1 |
MPS IIIB - Sanfilippo syndrome B
|
1 |
MPS IIIC - Sanfilippo syndrome C
|
1 |
MPS IIID - Sanfilippo syndrome D
|
1 |
MPS IV - Morquio syndrome A
|
1 |
MPS IV - Morquio syndrome B
|
1 |
MPS IX - Natowicz syndrome
|
1 |
MPS VI - Maroteaux-Lamy syndrome
|
1 |
MPS VII - Sly syndrome
|
1 |
MTF1 activates gene expression
|
3 |
Macroautophagy
|
68 |
Major pathway of rRNA processing in the nucleolus and cytosol
|
183 |
Meiosis
|
88 |
Meiotic recombination
|
56 |
Meiotic synapsis
|
60 |
Melanin biosynthesis
|
5 |
Membrane Trafficking
|
630 |
Membrane binding and targetting of GAG proteins
|
15 |
Metabolic disorders of biological oxidation enzymes
|
35 |
Metabolism
|
2116 |
Metabolism of Angiotensinogen to Angiotensins
|
17 |
Metabolism of RNA
|
673 |
Metabolism of amino acids and derivatives
|
371 |
Metabolism of carbohydrates
|
279 |
Metabolism of cofactors
|
19 |
Metabolism of fat-soluble vitamins
|
48 |
Metabolism of folate and pterines
|
18 |
Metabolism of ingested H2SeO4 and H2SeO3 into H2Se
|
4 |
Metabolism of ingested MeSeO2H into MeSeH
|
1 |
Metabolism of ingested SeMet, Sec, MeSec into H2Se
|
8 |
Metabolism of lipids
|
746 |
Metabolism of nitric oxide
|
15 |
Metabolism of non-coding RNA
|
55 |
Metabolism of nucleotides
|
103 |
Metabolism of polyamines
|
85 |
Metabolism of porphyrins
|
17 |
Metabolism of proteins
|
2111 |
Metabolism of serotonin
|
2 |
Metabolism of steroid hormones
|
34 |
Metabolism of steroids
|
152 |
Metabolism of vitamin K
|
3 |
Metabolism of vitamins and cofactors
|
192 |
Metabolism of water-soluble vitamins and cofactors
|
126 |
Metal ion SLC transporters
|
26 |
Metal sequestration by antimicrobial proteins
|
6 |
Metalloprotease DUBs
|
31 |
Metallothioneins bind metals
|
11 |
Methionine salvage pathway
|
6 |
Methylation
|
14 |
Methylation of MeSeH for excretion
|
1 |
MicroRNA (miRNA) biogenesis
|
24 |
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane
|
19 |
Mineralocorticoid biosynthesis
|
6 |
Minus-strand DNA synthesis
|
7 |
Miscellaneous substrates
|
12 |
Miscellaneous transport and binding events
|
26 |
Mismatch Repair
|
15 |
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
|
14 |
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)
|
14 |
Misspliced GSK3beta mutants stabilize beta-catenin
|
15 |
Misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
|
6 |
Mitochondrial ABC transporters
|
4 |
Mitochondrial Fatty Acid Beta-Oxidation
|
38 |
Mitochondrial Uncoupling Proteins
|
5 |
Mitochondrial biogenesis
|
96 |
Mitochondrial calcium ion transport
|
23 |
Mitochondrial iron-sulfur cluster biogenesis
|
13 |
Mitochondrial protein import
|
65 |
Mitochondrial tRNA aminoacylation
|
21 |
Mitochondrial transcription initiation
|
3 |
Mitochondrial transcription termination
|
1 |
Mitochondrial translation
|
94 |
Mitochondrial translation elongation
|
88 |
Mitochondrial translation initiation
|
88 |
Mitochondrial translation termination
|
88 |
Mitophagy
|
29 |
Mitotic Anaphase
|
201 |
Mitotic G1-G1/S phases
|
149 |
Mitotic G2-G2/M phases
|
199 |
Mitotic Metaphase and Anaphase
|
202 |
Mitotic Metaphase/Anaphase Transition
|
2 |
Mitotic Prometaphase
|
198 |
Mitotic Prophase
|
117 |
Mitotic Spindle Checkpoint
|
110 |
Mitotic Telophase/Cytokinesis
|
14 |
Molecules associated with elastic fibres
|
38 |
Molybdenum cofactor biosynthesis
|
8 |
Mtb iron assimilation by chelation
|
6 |
Mucopolysaccharidoses
|
11 |
Multifunctional anion exchangers
|
9 |
Muscarinic acetylcholine receptors
|
5 |
Muscle contraction
|
205 |
MyD88 cascade initiated on plasma membrane
|
85 |
MyD88 deficiency (TLR2/4)
|
11 |
MyD88 deficiency (TLR5)
|
3 |
MyD88 dependent cascade initiated on endosome
|
92 |
MyD88-independent TLR4 cascade
|
98 |
MyD88:Mal cascade initiated on plasma membrane
|
95 |
Myoclonic epilepsy of Lafora
|
11 |
Myogenesis
|
29 |
N-Glycan antennae elongation
|
15 |
N-glycan antennae elongation in the medial/trans-Golgi
|
26 |
N-glycan trimming and elongation in the cis-Golgi
|
5 |
N-glycan trimming in the ER and Calnexin/Calreticulin cycle
|
35 |
NADE modulates death signalling
|
6 |
NADPH regeneration
|
1 |
NCAM signaling for neurite out-growth
|
63 |
NCAM1 interactions
|
42 |
NEP/NS2 Interacts with the Cellular Export Machinery
|
40 |
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
|
12 |
NF-kB is activated and signals survival
|
13 |
NFG and proNGF binds to p75NTR
|
3 |
NGF processing
|
4 |
NGF-independant TRKA activation
|
5 |
NIK-->noncanonical NF-kB signaling
|
59 |
NOD1/2 Signaling Pathway
|
35 |
NOSIP mediated eNOS trafficking
|
2 |
NOSTRIN mediated eNOS trafficking
|
5 |
NOTCH1 Intracellular Domain Regulates Transcription
|
48 |
NOTCH2 Activation and Transmission of Signal to the Nucleus
|
22 |
NOTCH2 intracellular domain regulates transcription
|
12 |
NOTCH3 Activation and Transmission of Signal to the Nucleus
|
25 |
NOTCH3 Intracellular Domain Regulates Transcription
|
25 |
NOTCH4 Activation and Transmission of Signal to the Nucleus
|
11 |
NOTCH4 Intracellular Domain Regulates Transcription
|
20 |
NR1D1 (REV-ERBA) represses gene expression
|
3 |
NRAGE signals death through JNK
|
59 |
NRIF signals cell death from the nucleus
|
16 |
NS1 Mediated Effects on Host Pathways
|
44 |
NTF3 activates NTRK2 (TRKB) signaling
|
2 |
NTF3 activates NTRK3 signaling
|
2 |
NTF4 activates NTRK2 (TRKB) signaling
|
2 |
NTRK2 activates RAC1
|
5 |
NTRK3 as a dependence receptor
|
3 |
Na+/Cl- dependent neurotransmitter transporters
|
19 |
Nectin/Necl trans heterodimerization
|
7 |
Neddylation
|
236 |
Nef Mediated CD4 Down-regulation
|
10 |
Nef Mediated CD8 Down-regulation
|
8 |
Nef and signal transduction
|
9 |
Nef mediated downregulation of CD28 cell surface expression
|
3 |
Nef mediated downregulation of MHC class I complex cell surface expression
|
11 |
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
|
22 |
Negative epigenetic regulation of rRNA expression
|
78 |
Negative feedback regulation of MAPK pathway
|
6 |
Negative regulation of FGFR1 signaling
|
35 |
Negative regulation of FGFR2 signaling
|
37 |
Negative regulation of FGFR3 signaling
|
30 |
Negative regulation of FGFR4 signaling
|
31 |
Negative regulation of MAPK pathway
|
40 |
Negative regulation of MET activity
|
21 |
Negative regulation of NOTCH4 signaling
|
55 |
Negative regulation of TCF-dependent signaling by DVL-interacting proteins
|
5 |
Negative regulation of TCF-dependent signaling by WNT ligand antagonists
|
15 |
Negative regulation of activity of TFAP2 (AP-2) family transcription factors
|
11 |
Negative regulation of the PI3K/AKT network
|
115 |
Negative regulators of DDX58/IFIH1 signaling
|
34 |
Nephrin family interactions
|
23 |
Netrin mediated repulsion signals
|
8 |
Netrin-1 signaling
|
50 |
Neurexins and neuroligins
|
60 |
Neurodegenerative Diseases
|
23 |
Neurofascin interactions
|
7 |
Neuronal System
|
370 |
Neurophilin interactions with VEGF and VEGFR
|
4 |
Neurotoxicity of clostridium toxins
|
22 |
Neurotransmitter clearance
|
10 |
Neurotransmitter receptors and postsynaptic signal transmission
|
152 |
Neurotransmitter release cycle
|
51 |
Neurotransmitter uptake and metabolism In glial cells
|
4 |
Neutrophil degranulation
|
480 |
Nicotinamide salvaging
|
19 |
Nicotinate metabolism
|
31 |
Nitric oxide stimulates guanylate cyclase
|
25 |
NoRC negatively regulates rRNA expression
|
75 |
Non-integrin membrane-ECM interactions
|
59 |
Noncanonical activation of NOTCH3
|
8 |
Nonhomologous End-Joining (NHEJ)
|
52 |
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
|
117 |
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
|
96 |
Nonsense-Mediated Decay (NMD)
|
117 |
Norepinephrine Neurotransmitter Release Cycle
|
18 |
Notch-HLH transcription pathway
|
13 |
NrCAM interactions
|
7 |
Nuclear Envelope Breakdown
|
56 |
Nuclear Envelope Reassembly
|
14 |
Nuclear Events (kinase and transcription factor activation)
|
25 |
Nuclear Pore Complex (NPC) Disassembly
|
38 |
Nuclear Receptor transcription pathway
|
84 |
Nuclear import of Rev protein
|
37 |
Nuclear signaling by ERBB4
|
27 |
Nucleobase biosynthesis
|
15 |
Nucleobase catabolism
|
39 |
Nucleosome assembly
|
54 |
Nucleotide Excision Repair
|
110 |
Nucleotide salvage
|
23 |
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
|
58 |
Nucleotide-like (purinergic) receptors
|
16 |
O-glycosylation of TSR domain-containing proteins
|
39 |
O-linked glycosylation
|
115 |
O-linked glycosylation of mucins
|
66 |
O2/CO2 exchange in erythrocytes
|
12 |
Olfactory Signaling Pathway
|
432 |
Oligomerization of connexins into connexons
|
3 |
Oncogene Induced Senescence
|
34 |
Oncogenic MAPK signaling
|
77 |
Opioid Signalling
|
81 |
Opsins
|
9 |
Orc1 removal from chromatin
|
71 |
Orexin and neuropeptides FF and QRFP bind to their respective receptors
|
8 |
Organelle biogenesis and maintenance
|
297 |
Organic anion transport
|
5 |
Organic anion transporters
|
10 |
Organic cation transport
|
10 |
Organic cation/anion/zwitterion transport
|
15 |
Other interleukin signaling
|
26 |
Other semaphorin interactions
|
19 |
Ovarian tumor domain proteases
|
38 |
Oxidative Stress Induced Senescence
|
94 |
Oxygen-dependent asparagine hydroxylation of Hypoxia-inducible Factor Alpha
|
3 |
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
|
66 |
P2Y receptors
|
12 |
PAOs oxidise polyamines to amines
|
2 |
PCNA-Dependent Long Patch Base Excision Repair
|
21 |
PCP/CE pathway
|
92 |
PD-1 signaling
|
42 |
PDE3B signalling
|
2 |
PECAM1 interactions
|
12 |
PERK regulates gene expression
|
28 |
PI Metabolism
|
84 |
PI and PC transport between ER and Golgi membranes
|
1 |
PI-3K cascade:FGFR1
|
23 |
PI-3K cascade:FGFR2
|
26 |
PI-3K cascade:FGFR3
|
19 |
PI-3K cascade:FGFR4
|
20 |
PI3K Cascade
|
50 |
PI3K events in ERBB2 signaling
|
18 |
PI3K events in ERBB4 signaling
|
11 |
PI3K/AKT Signaling in Cancer
|
106 |
PI3K/AKT activation
|
9 |
PI5P Regulates TP53 Acetylation
|
9 |
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
|
108 |
PIP3 activates AKT signaling
|
269 |
PIWI-interacting RNA (piRNA) biogenesis
|
29 |
PKA activation
|
17 |
PKA activation in glucagon signalling
|
18 |
PKA-mediated phosphorylation of CREB
|
18 |
PKA-mediated phosphorylation of key metabolic factors
|
5 |
PKB-mediated events
|
2 |
PKMTs methylate histone lysines
|
47 |
PLC beta mediated events
|
44 |
PLC-gamma1 signalling
|
3 |
PLCG1 events in ERBB2 signaling
|
4 |
POLB-Dependent Long Patch Base Excision Repair
|
8 |
POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation
|
13 |
POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation
|
3 |
PP2A-mediated dephosphorylation of key metabolic factors
|
7 |
PPARA activates gene expression
|
118 |
PRC2 methylates histones and DNA
|
42 |
PTEN Loss of Function in Cancer
|
1 |
PTEN Regulation
|
139 |
PTK6 Activates STAT3
|
4 |
PTK6 Down-Regulation
|
3 |
PTK6 Expression
|
5 |
PTK6 Regulates Cell Cycle
|
6 |
PTK6 Regulates Proteins Involved in RNA Processing
|
5 |
PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
|
14 |
PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
|
9 |
PTK6 promotes HIF1A stabilization
|
6 |
Packaging Of Telomere Ends
|
33 |
Packaging of Eight RNA Segments
|
9 |
Paradoxical activation of RAF signaling by kinase inactive BRAF
|
41 |
Passive transport by Aquaporins
|
13 |
Pausing and recovery of HIV elongation
|
36 |
Pausing and recovery of Tat-mediated HIV elongation
|
35 |
Pentose phosphate pathway
|
15 |
Pentose phosphate pathway disease
|
2 |
Peptide chain elongation
|
90 |
Peptide hormone biosynthesis
|
12 |
Peptide hormone metabolism
|
88 |
Peptide ligand-binding receptors
|
189 |
Peroxisomal lipid metabolism
|
29 |
Peroxisomal protein import
|
64 |
Phase 0 - rapid depolarisation
|
45 |
Phase 1 - inactivation of fast Na+ channels
|
7 |
Phase 2 - plateau phase
|
28 |
Phase 3 - rapid repolarisation
|
8 |
Phase 4 - resting membrane potential
|
19 |
Phase I - Functionalization of compounds
|
106 |
Phase II - Conjugation of compounds
|
110 |
Phenylalanine and tyrosine catabolism
|
11 |
Phenylketonuria
|
1 |
Phosphate bond hydrolysis by NTPDase proteins
|
8 |
Phosphate bond hydrolysis by NUDT proteins
|
10 |
Phospholipase C-mediated cascade: FGFR1
|
18 |
Phospholipase C-mediated cascade; FGFR2
|
21 |
Phospholipase C-mediated cascade; FGFR3
|
14 |
Phospholipase C-mediated cascade; FGFR4
|
15 |
Phospholipid metabolism
|
212 |
Phosphorylation of CD3 and TCR zeta chains
|
41 |
Phosphorylation of Emi1
|
6 |
Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes
|
4 |
Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2 complexes
|
3 |
Phosphorylation of the APC/C
|
19 |
Physiological factors
|
12 |
Pink/Parkin Mediated Mitophagy
|
22 |
Plasma lipoprotein assembly
|
19 |
Plasma lipoprotein assembly, remodeling, and clearance
|
72 |
Plasma lipoprotein clearance
|
33 |
Plasma lipoprotein remodeling
|
33 |
Plasmalogen biosynthesis
|
2 |
Platelet Adhesion to exposed collagen
|
15 |
Platelet Aggregation (Plug Formation)
|
40 |
Platelet activation, signaling and aggregation
|
262 |
Platelet calcium homeostasis
|
28 |
Platelet degranulation
|
128 |
Platelet homeostasis
|
90 |
Platelet sensitization by LDL
|
17 |
Plus-strand DNA synthesis
|
7 |
Polo-like kinase mediated events
|
16 |
Polymerase switching
|
14 |
Polymerase switching on the C-strand of the telomere
|
14 |
Positive epigenetic regulation of rRNA expression
|
75 |
Post NMDA receptor activation events
|
35 |
Post-chaperonin tubulin folding pathway
|
22 |
Post-transcriptional silencing by small RNAs
|
7 |
Post-translational modification: synthesis of GPI-anchored proteins
|
94 |
Post-translational protein modification
|
1415 |
Post-translational protein phosphorylation
|
107 |
Postsynaptic nicotinic acetylcholine receptors
|
14 |
Potassium Channels
|
99 |
Potassium transport channels
|
3 |
Pre-NOTCH Expression and Processing
|
78 |
Pre-NOTCH Processing in Golgi
|
18 |
Pre-NOTCH Processing in the Endoplasmic Reticulum
|
6 |
Pre-NOTCH Transcription and Translation
|
62 |
Prefoldin mediated transfer of substrate to CCT/TriC
|
27 |
Pregnenolone biosynthesis
|
12 |
Presynaptic depolarization and calcium channel opening
|
13 |
Presynaptic function of Kainate receptors
|
21 |
Presynaptic nicotinic acetylcholine receptors
|
12 |
Presynaptic phase of homologous DNA pairing and strand exchange
|
39 |
Processing and activation of SUMO
|
10 |
Processing of Capped Intron-Containing Pre-mRNA
|
243 |
Processing of Capped Intronless Pre-mRNA
|
28 |
Processing of DNA double-strand break ends
|
81 |
Processing of Intronless Pre-mRNAs
|
19 |
Processing of SMDT1
|
16 |
Processive synthesis on the C-strand of the telomere
|
11 |
Processive synthesis on the lagging strand
|
15 |
Programmed Cell Death
|
176 |
Progressive trimming of alpha-1,2-linked mannose residues from Man9/8/7GlcNAc2 to produce Man5GlcNAc2
|
3 |
Prolactin receptor signaling
|
15 |
Proline catabolism
|
3 |
Prolonged ERK activation events
|
12 |
Propionyl-CoA catabolism
|
5 |
Prostacyclin signalling through prostacyclin receptor
|
20 |
Prostanoid ligand receptors
|
9 |
Protein folding
|
101 |
Protein methylation
|
17 |
Protein repair
|
6 |
Protein ubiquitination
|
79 |
Protein-protein interactions at synapses
|
91 |
Proton-coupled monocarboxylate transport
|
6 |
Proton-coupled neutral amino acid transporters
|
2 |
Proton/oligopeptide cotransporters
|
4 |
Purine catabolism
|
21 |
Purine ribonucleoside monophosphate biosynthesis
|
12 |
Purine salvage
|
13 |
Pyrimidine biosynthesis
|
3 |
Pyrimidine catabolism
|
12 |
Pyrimidine salvage
|
11 |
Pyrophosphate hydrolysis
|
2 |
Pyruvate metabolism
|
31 |
Pyruvate metabolism and Citric Acid (TCA) cycle
|
55 |
RA biosynthesis pathway
|
22 |
RAB GEFs exchange GTP for GDP on RABs
|
90 |
RAB geranylgeranylation
|
65 |
RAF activation
|
25 |
RAF-independent MAPK1/3 activation
|
24 |
RAF/MAP kinase cascade
|
256 |
RAS signaling downstream of NF1 loss-of-function variants
|
4 |
RET signaling
|
41 |
RHO GTPase Effectors
|
285 |
RHO GTPases Activate Formins
|
140 |
RHO GTPases Activate NADPH Oxidases
|
13 |
RHO GTPases Activate ROCKs
|
19 |
RHO GTPases Activate Rhotekin and Rhophilins
|
9 |
RHO GTPases Activate WASPs and WAVEs
|
36 |
RHO GTPases activate CIT
|
20 |
RHO GTPases activate IQGAPs
|
31 |
RHO GTPases activate KTN1
|
11 |
RHO GTPases activate PAKs
|
21 |
RHO GTPases activate PKNs
|
63 |
RHO GTPases regulate CFTR trafficking
|
3 |
RIP-mediated NFkB activation via ZBP1
|
17 |
RIPK1-mediated regulated necrosis
|
23 |
RMTs methylate histone arginines
|
49 |
RNA Pol II CTD phosphorylation and interaction with CE
|
27 |
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection
|
27 |
RNA Polymerase I Chain Elongation
|
59 |
RNA Polymerase I Promoter Clearance
|
78 |
RNA Polymerase I Promoter Escape
|
30 |
RNA Polymerase I Promoter Opening
|
32 |
RNA Polymerase I Transcription
|
80 |
RNA Polymerase I Transcription Initiation
|
47 |
RNA Polymerase I Transcription Termination
|
31 |
RNA Polymerase II HIV Promoter Escape
|
47 |
RNA Polymerase II Pre-transcription Events
|
84 |
RNA Polymerase II Promoter Escape
|
47 |
RNA Polymerase II Transcription
|
1274 |
RNA Polymerase II Transcription Elongation
|
61 |
RNA Polymerase II Transcription Initiation
|
47 |
RNA Polymerase II Transcription Initiation And Promoter Clearance
|
47 |
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
|
47 |
RNA Polymerase II Transcription Termination
|
66 |
RNA Polymerase III Abortive And Retractive Initiation
|
41 |
RNA Polymerase III Chain Elongation
|
18 |
RNA Polymerase III Transcription
|
41 |
RNA Polymerase III Transcription Initiation
|
36 |
RNA Polymerase III Transcription Initiation From Type 1 Promoter
|
28 |
RNA Polymerase III Transcription Initiation From Type 2 Promoter
|
27 |
RNA Polymerase III Transcription Initiation From Type 3 Promoter
|
28 |
RNA Polymerase III Transcription Termination
|
23 |
RNA polymerase II transcribes snRNA genes
|
74 |
RNF mutants show enhanced WNT signaling and proliferation
|
8 |
ROBO receptors bind AKAP5
|
9 |
RORA activates gene expression
|
18 |
ROS, RNS production in phagocytes
|
32 |
RPIA deficiency: failed conversion of R5P to RU5P
|
1 |
RPIA deficiency: failed conversion of RU5P to R5P
|
1 |
RSK activation
|
6 |
RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)
|
10 |
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
|
37 |
RUNX1 regulates estrogen receptor mediated transcription
|
6 |
RUNX1 regulates expression of components of tight junctions
|
5 |
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
|
66 |
RUNX1 regulates transcription of genes involved in BCR signaling
|
6 |
RUNX1 regulates transcription of genes involved in WNT signaling
|
6 |
RUNX1 regulates transcription of genes involved in differentiation of HSCs
|
99 |
RUNX1 regulates transcription of genes involved in differentiation of keratinocytes
|
8 |
RUNX1 regulates transcription of genes involved in differentiation of myeloid cells
|
8 |
RUNX1 regulates transcription of genes involved in interleukin signaling
|
5 |
RUNX2 regulates bone development
|
32 |
RUNX2 regulates chondrocyte maturation
|
6 |
RUNX2 regulates genes involved in cell migration
|
9 |
RUNX2 regulates genes involved in differentiation of myeloid cells
|
5 |
RUNX2 regulates osteoblast differentiation
|
25 |
RUNX3 Regulates Immune Response and Cell Migration
|
6 |
RUNX3 regulates BCL2L11 (BIM) transcription
|
5 |
RUNX3 regulates CDKN1A transcription
|
7 |
RUNX3 regulates NOTCH signaling
|
14 |
RUNX3 regulates RUNX1-mediated transcription
|
2 |
RUNX3 regulates WNT signaling
|
8 |
RUNX3 regulates YAP1-mediated transcription
|
8 |
RUNX3 regulates p14-ARF
|
9 |
Rab regulation of trafficking
|
123 |
Rap1 signalling
|
16 |
Ras activation upon Ca2+ influx through NMDA receptor
|
17 |
Reactions specific to the complex N-glycan synthesis pathway
|
10 |
Reactions specific to the hybrid N-glycan synthesis pathway
|
1 |
Receptor Mediated Mitophagy
|
11 |
Receptor-type tyrosine-protein phosphatases
|
20 |
Recognition and association of DNA glycosylase with site containing an affected purine
|
4 |
Recognition and association of DNA glycosylase with site containing an affected pyrimidine
|
8 |
Recognition of DNA damage by PCNA-containing replication complex
|
31 |
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
|
59 |
Recruitment of NuMA to mitotic centrosomes
|
94 |
Recruitment of mitotic centrosome proteins and complexes
|
81 |
Recycling of bile acids and salts
|
16 |
Recycling of eIF2:GDP
|
8 |
Recycling pathway of L1
|
48 |
Reduction of cytosolic Ca++ levels
|
12 |
Reelin signalling pathway
|
5 |
Regulated Necrosis
|
23 |
Regulated proteolysis of p75NTR
|
11 |
Regulation by TREX1
|
1 |
Regulation by c-FLIP
|
11 |
Regulation of APC/C activators between G1/S and early anaphase
|
80 |
Regulation of Apoptosis
|
53 |
Regulation of Complement cascade
|
135 |
Regulation of FZD by ubiquitination
|
21 |
Regulation of Glucokinase by Glucokinase Regulatory Protein
|
34 |
Regulation of HSF1-mediated heat shock response
|
73 |
Regulation of Hypoxia-inducible Factor (HIF) by oxygen
|
75 |
Regulation of IFNA signaling
|
26 |
Regulation of IFNG signaling
|
14 |
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
|
124 |
Regulation of KIT signaling
|
16 |
Regulation of PAK-2p34 activity by PS-GAP/RHG10
|
2 |
Regulation of PLK1 Activity at G2/M Transition
|
87 |
Regulation of PTEN gene transcription
|
60 |
Regulation of PTEN localization
|
9 |
Regulation of PTEN mRNA translation
|
9 |
Regulation of PTEN stability and activity
|
69 |
Regulation of RAS by GAPs
|
68 |
Regulation of RUNX1 Expression and Activity
|
17 |
Regulation of RUNX2 expression and activity
|
74 |
Regulation of RUNX3 expression and activity
|
55 |
Regulation of TLR by endogenous ligand
|
19 |
Regulation of TNFR1 signaling
|
37 |
Regulation of TP53 Activity
|
160 |
Regulation of TP53 Activity through Acetylation
|
30 |
Regulation of TP53 Activity through Association with Co-factors
|
14 |
Regulation of TP53 Activity through Methylation
|
19 |
Regulation of TP53 Activity through Phosphorylation
|
92 |
Regulation of TP53 Degradation
|
36 |
Regulation of TP53 Expression
|
2 |
Regulation of TP53 Expression and Degradation
|
37 |
Regulation of actin dynamics for phagocytic cup formation
|
150 |
Regulation of activated PAK-2p34 by proteasome mediated degradation
|
50 |
Regulation of beta-cell development
|
44 |
Regulation of cholesterol biosynthesis by SREBP (SREBF)
|
56 |
Regulation of commissural axon pathfinding by SLIT and ROBO
|
10 |
Regulation of cortical dendrite branching
|
4 |
Regulation of cytoskeletal remodeling and cell spreading by IPP complex components
|
8 |
Regulation of expression of SLITs and ROBOs
|
172 |
Regulation of gap junction activity
|
3 |
Regulation of gene expression by Hypoxia-inducible Factor
|
11 |
Regulation of gene expression in beta cells
|
23 |
Regulation of gene expression in early pancreatic precursor cells
|
8 |
Regulation of gene expression in endocrine-committed (NEUROG3+) progenitor cells
|
5 |
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
|
16 |
Regulation of innate immune responses to cytosolic DNA
|
15 |
Regulation of insulin secretion
|
81 |
Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
120 |
Regulation of mRNA stability by proteins that bind AU-rich elements
|
88 |
Regulation of mitotic cell cycle
|
86 |
Regulation of necroptotic cell death
|
21 |
Regulation of ornithine decarboxylase (ODC)
|
51 |
Regulation of pyruvate dehydrogenase (PDH) complex
|
16 |
Regulation of signaling by CBL
|
22 |
Regulation of signaling by NODAL
|
12 |
Regulation of thyroid hormone activity
|
3 |
Relaxin receptors
|
8 |
Release
|
9 |
Release of Hh-Np from the secreting cell
|
8 |
Release of apoptotic factors from the mitochondria
|
4 |
Removal of aminoterminal propeptides from gamma-carboxylated proteins
|
10 |
Removal of the Flap Intermediate
|
14 |
Removal of the Flap Intermediate from the C-strand
|
10 |
Repression of WNT target genes
|
12 |
Reproduction
|
114 |
Resolution of AP sites via the multiple-nucleotide patch replacement pathway
|
25 |
Resolution of AP sites via the single-nucleotide replacement pathway
|
4 |
Resolution of Abasic Sites (AP sites)
|
39 |
Resolution of D-Loop Structures
|
33 |
Resolution of D-loop Structures through Holliday Junction Intermediates
|
32 |
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
|
26 |
Resolution of Sister Chromatid Cohesion
|
125 |
Respiratory electron transport
|
101 |
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.
|
124 |
Response of Mtb to phagocytosis
|
35 |
Response to elevated platelet cytosolic Ca2+
|
133 |
Response to metal ions
|
14 |
Retinoid cycle disease events
|
13 |
Retinoid metabolism and transport
|
44 |
Retinoid metabolism disease events
|
1 |
Retrograde neurotrophin signalling
|
14 |
Retrograde transport at the Trans-Golgi-Network
|
49 |
Reuptake of GABA
|
4 |
Rev-mediated nuclear export of HIV RNA
|
38 |
Reversal of alkylation damage by DNA dioxygenases
|
7 |
Reverse Transcription of HIV RNA
|
7 |
Reversible hydration of carbon dioxide
|
12 |
Rhesus glycoproteins mediate ammonium transport.
|
3 |
Rho GTPase cycle
|
141 |
Ribosomal scanning and start codon recognition
|
59 |
Role of ABL in ROBO-SLIT signaling
|
8 |
Role of LAT2/NTAL/LAB on calcium mobilization
|
102 |
Role of phospholipids in phagocytosis
|
114 |
Role of second messengers in netrin-1 signaling
|
10 |
S Phase
|
161 |
S33 mutants of beta-catenin aren't phosphorylated
|
15 |
S37 mutants of beta-catenin aren't phosphorylated
|
15 |
S45 mutants of beta-catenin aren't phosphorylated
|
15 |
SCF(Skp2)-mediated degradation of p27/p21
|
60 |
SCF-beta-TrCP mediated degradation of Emi1
|
55 |
SDK interactions
|
2 |
SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
|
14 |
SHC-mediated cascade:FGFR1
|
24 |
SHC-mediated cascade:FGFR2
|
27 |
SHC-mediated cascade:FGFR3
|
20 |
SHC-mediated cascade:FGFR4
|
21 |
SHC-related events triggered by IGF1R
|
11 |
SHC1 events in EGFR signaling
|
8 |
SHC1 events in ERBB2 signaling
|
27 |
SHC1 events in ERBB4 signaling
|
16 |
SIRT1 negatively regulates rRNA expression
|
37 |
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs
|
11 |
SLBP independent Processing of Histone Pre-mRNAs
|
10 |
SLC transporter disorders
|
68 |
SLC-mediated transmembrane transport
|
246 |
SLIT2:ROBO1 increases RHOA activity
|
4 |
SMAC binds to IAPs
|
5 |
SMAC-mediated apoptotic response
|
5 |
SMAC-mediated dissociation of IAP:caspase complexes
|
5 |
SMAD2/3 MH2 Domain Mutants in Cancer
|
7 |
SMAD2/3 Phosphorylation Motif Mutants in Cancer
|
6 |
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
|
32 |
SMAD4 MH2 Domain Mutants in Cancer
|
3 |
SOS-mediated signalling
|
7 |
SRP-dependent cotranslational protein targeting to membrane
|
113 |
STAT6-mediated induction of chemokines
|
3 |
STING mediated induction of host immune responses
|
16 |
SUMO E3 ligases SUMOylate target proteins
|
172 |
SUMO is conjugated to E1 (UBA2:SAE1)
|
5 |
SUMO is proteolytically processed
|
6 |
SUMO is transferred from E1 to E2 (UBE2I, UBC9)
|
7 |
SUMOylation
|
178 |
SUMOylation of DNA damage response and repair proteins
|
79 |
SUMOylation of DNA methylation proteins
|
16 |
SUMOylation of DNA replication proteins
|
48 |
SUMOylation of RNA binding proteins
|
49 |
SUMOylation of SUMOylation proteins
|
37 |
SUMOylation of chromatin organization proteins
|
60 |
SUMOylation of immune response proteins
|
11 |
SUMOylation of intracellular receptors
|
31 |
SUMOylation of transcription cofactors
|
44 |
SUMOylation of transcription factors
|
20 |
SUMOylation of ubiquitinylation proteins
|
41 |
Scavenging by Class A Receptors
|
19 |
Scavenging by Class B Receptors
|
6 |
Scavenging by Class F Receptors
|
7 |
Scavenging by Class H Receptors
|
4 |
Scavenging of heme from plasma
|
99 |
SeMet incorporation into proteins
|
11 |
Selenoamino acid metabolism
|
118 |
Selenocysteine synthesis
|
94 |
Sema3A PAK dependent Axon repulsion
|
16 |
Sema4D in semaphorin signaling
|
24 |
Sema4D induced cell migration and growth-cone collapse
|
20 |
Sema4D mediated inhibition of cell attachment and migration
|
8 |
Semaphorin interactions
|
64 |
Senescence-Associated Secretory Phenotype (SASP)
|
79 |
Sensing of DNA Double Strand Breaks
|
6 |
Separation of Sister Chromatids
|
189 |
Serine biosynthesis
|
9 |
Serotonin Neurotransmitter Release Cycle
|
18 |
Serotonin and melatonin biosynthesis
|
5 |
Serotonin clearance from the synaptic cleft
|
3 |
Serotonin receptors
|
12 |
Severe congenital neutropenia type 4 (G6PC3)
|
1 |
Sialic acid metabolism
|
33 |
Signal Transduction
|
2738 |
Signal amplification
|
32 |
Signal attenuation
|
10 |
Signal regulatory protein family interactions
|
16 |
Signal transduction by L1
|
21 |
Signaling by Activin
|
13 |
Signaling by BMP
|
28 |
Signaling by BRAF and RAF fusions
|
61 |
Signaling by EGFR
|
44 |
Signaling by EGFR in Cancer
|
19 |
Signaling by EGFRvIII in Cancer
|
15 |
Signaling by ERBB2
|
55 |
Signaling by ERBB4
|
47 |
Signaling by FGFR
|
94 |
Signaling by FGFR in disease
|
72 |
Signaling by FGFR1
|
53 |
Signaling by FGFR1 amplification mutants
|
2 |
Signaling by FGFR1 in disease
|
40 |
Signaling by FGFR2
|
77 |
Signaling by FGFR2 IIIa TM
|
23 |
Signaling by FGFR2 amplification mutants
|
2 |
Signaling by FGFR2 fusions
|
1 |
Signaling by FGFR2 in disease
|
48 |
Signaling by FGFR3
|
42 |
Signaling by FGFR3 fusions in cancer
|
10 |
Signaling by FGFR3 in disease
|
24 |
Signaling by FGFR3 point mutants in cancer
|
24 |
Signaling by FGFR4
|
42 |
Signaling by FGFR4 in disease
|
11 |
Signaling by GPCR
|
1209 |
Signaling by Hedgehog
|
149 |
Signaling by Hippo
|
20 |
Signaling by Insulin receptor
|
84 |
Signaling by Interleukins
|
457 |
Signaling by Leptin
|
11 |
Signaling by Ligand-Responsive EGFR Variants in Cancer
|
19 |
Signaling by MET
|
79 |
Signaling by MST1
|
5 |
Signaling by NODAL
|
21 |
Signaling by NOTCH
|
205 |
Signaling by NOTCH1
|
74 |
Signaling by NOTCH1 HD Domain Mutants in Cancer
|
15 |
Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
|
59 |
Signaling by NOTCH1 PEST Domain Mutants in Cancer
|
59 |
Signaling by NOTCH1 in Cancer
|
59 |
Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
|
7 |
Signaling by NOTCH2
|
33 |
Signaling by NOTCH3
|
49 |
Signaling by NOTCH4
|
83 |
Signaling by NTRK1 (TRKA)
|
79 |
Signaling by NTRK2 (TRKB)
|
26 |
Signaling by NTRK3 (TRKC)
|
18 |
Signaling by NTRKs
|
103 |
Signaling by Non-Receptor Tyrosine Kinases
|
57 |
Signaling by Nuclear Receptors
|
169 |
Signaling by Overexpressed Wild-Type EGFR in Cancer
|
2 |
Signaling by PDGF
|
59 |
Signaling by PTK6
|
57 |
Signaling by RAS mutants
|
54 |
Signaling by ROBO receptors
|
218 |
Signaling by Receptor Tyrosine Kinases
|
471 |
Signaling by Retinoic Acid
|
43 |
Signaling by Rho GTPases
|
416 |
Signaling by SCF-KIT
|
44 |
Signaling by TGF-beta Receptor Complex
|
73 |
Signaling by TGF-beta Receptor Complex in Cancer
|
8 |
Signaling by TGF-beta family members
|
102 |
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
|
62 |
Signaling by VEGF
|
106 |
Signaling by WNT
|
297 |
Signaling by WNT in cancer
|
34 |
Signaling by activated point mutants of FGFR1
|
12 |
Signaling by activated point mutants of FGFR3
|
14 |
Signaling by cytosolic FGFR1 fusion mutants
|
18 |
Signaling by high-kinase activity BRAF mutants
|
36 |
Signaling by moderate kinase activity BRAF mutants
|
41 |
Signaling by plasma membrane FGFR1 fusions
|
3 |
Signaling by the B Cell Receptor (BCR)
|
180 |
Signalling to ERK5
|
2 |
Signalling to ERKs
|
32 |
Signalling to RAS
|
20 |
Signalling to STAT3
|
3 |
Signalling to p38 via RIT and RIN
|
5 |
Small interfering RNA (siRNA) biogenesis
|
9 |
Smooth Muscle Contraction
|
35 |
Sodium-coupled phosphate cotransporters
|
5 |
Sodium-coupled sulphate, di- and tri-carboxylate transporters
|
5 |
Sodium/Calcium exchangers
|
11 |
Sodium/Proton exchangers
|
9 |
Sperm Motility And Taxes
|
9 |
Sperm:Oocyte Membrane Binding
|
5 |
Sphingolipid de novo biosynthesis
|
44 |
Sphingolipid metabolism
|
90 |
Spry regulation of FGF signaling
|
16 |
Stabilization of p53
|
57 |
Sterols are 12-hydroxylated by CYP8B1
|
2 |
Stimulation of the cell death response by PAK-2p34
|
2 |
Stimuli-sensing channels
|
107 |
Striated Muscle Contraction
|
36 |
Sulfide oxidation to sulfate
|
6 |
Sulfur amino acid metabolism
|
27 |
Surfactant metabolism
|
30 |
Switching of origins to a post-replicative state
|
90 |
Synaptic adhesion-like molecules
|
21 |
Syndecan interactions
|
27 |
Synthesis And Processing Of GAG, GAGPOL Polyproteins
|
15 |
Synthesis and processing of ENV and VPU
|
3 |
Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)
|
9 |
Synthesis of 12-eicosatetraenoic acid derivatives
|
7 |
Synthesis of 15-eicosatetraenoic acid derivatives
|
6 |
Synthesis of 5-eicosatetraenoic acids
|
9 |
Synthesis of CL
|
1 |
Synthesis of DNA
|
119 |
Synthesis of Dolichyl-phosphate
|
6 |
Synthesis of GDP-mannose
|
5 |
Synthesis of Hepoxilins (HX) and Trioxilins (TrX)
|
1 |
Synthesis of IP2, IP, and Ins in the cytosol
|
14 |
Synthesis of IP3 and IP4 in the cytosol
|
26 |
Synthesis of IPs in the ER lumen
|
1 |
Synthesis of IPs in the nucleus
|
4 |
Synthesis of Ketone Bodies
|
8 |
Synthesis of Leukotrienes (LT) and Eoxins (EX)
|
21 |
Synthesis of Lipoxins (LX)
|
6 |
Synthesis of PA
|
39 |
Synthesis of PC
|
28 |
Synthesis of PE
|
13 |
Synthesis of PG
|
8 |
Synthesis of PI
|
5 |
Synthesis of PIPs at the ER membrane
|
5 |
Synthesis of PIPs at the Golgi membrane
|
18 |
Synthesis of PIPs at the early endosome membrane
|
16 |
Synthesis of PIPs at the late endosome membrane
|
11 |
Synthesis of PIPs at the plasma membrane
|
53 |
Synthesis of PIPs in the nucleus
|
4 |
Synthesis of PS
|
2 |
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)
|
15 |
Synthesis of UDP-N-acetyl-glucosamine
|
8 |
Synthesis of active ubiquitin: roles of E1 and E2 enzymes
|
30 |
Synthesis of bile acids and bile salts
|
34 |
Synthesis of bile acids and bile salts via 24-hydroxycholesterol
|
14 |
Synthesis of bile acids and bile salts via 27-hydroxycholesterol
|
15 |
Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol
|
24 |
Synthesis of diphthamide-EEF2
|
8 |
Synthesis of dolichyl-phosphate mannose
|
3 |
Synthesis of dolichyl-phosphate-glucose
|
2 |
Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)
|
8 |
Synthesis of glycosylphosphatidylinositol (GPI)
|
18 |
Synthesis of pyrophosphates in the cytosol
|
10 |
Synthesis of substrates in N-glycan biosythesis
|
63 |
Synthesis of very long-chain fatty acyl-CoAs
|
24 |
Synthesis of wybutosine at G37 of tRNA(Phe)
|
6 |
Synthesis, secretion, and deacylation of Ghrelin
|
20 |
Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
|
20 |
Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)
|
13 |
T41 mutants of beta-catenin aren't phosphorylated
|
15 |
TAK1 activates NFkB by phosphorylation and activation of IKKs complex
|
32 |
TALDO1 deficiency: failed conversion of Fru(6)P, E4P to SH7P, GA3P
|
1 |
TALDO1 deficiency: failed conversion of SH7P, GA3P to Fru(6)P, E4P
|
1 |
TBC/RABGAPs
|
45 |
TCF dependent signaling in response to WNT
|
202 |
TCF7L2 mutants don't bind CTBP
|
3 |
TCR signaling
|
137 |
TET1,2,3 and TDG demethylate DNA
|
4 |
TFAP2 (AP-2) family regulates transcription of cell cycle factors
|
5 |
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
|
13 |
TFAP2 (AP-2) family regulates transcription of other transcription factors
|
4 |
TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation
|
5 |
TGF-beta receptor signaling activates SMADs
|
32 |
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
|
16 |
TGFBR1 KD Mutants in Cancer
|
7 |
TGFBR1 LBD Mutants in Cancer
|
4 |
TGFBR2 Kinase Domain Mutants in Cancer
|
4 |
TGFBR2 MSI Frameshift Mutants in Cancer
|
2 |
TICAM1 deficiency - HSE
|
2 |
TICAM1, RIP1-mediated IKK complex recruitment
|
19 |
TICAM1,TRAF6-dependent induction of TAK1 complex
|
16 |
TICAM1-dependent activation of IRF3/IRF7
|
12 |
TLR3 deficiency - HSE
|
1 |
TLR3-mediated TICAM1-dependent programmed cell death
|
6 |
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway
|
17 |
TNF signaling
|
47 |
TNFR1-induced NFkappaB signaling pathway
|
30 |
TNFR1-induced proapoptotic signaling
|
14 |
TNFR1-mediated ceramide production
|
6 |
TNFR2 non-canonical NF-kB pathway
|
102 |
TNFs bind their physiological receptors
|
30 |
TP53 Regulates Metabolic Genes
|
88 |
TP53 Regulates Transcription of Caspase Activators and Caspases
|
12 |
TP53 Regulates Transcription of Cell Cycle Genes
|
49 |
TP53 Regulates Transcription of Cell Death Genes
|
44 |
TP53 Regulates Transcription of DNA Repair Genes
|
65 |
TP53 Regulates Transcription of Death Receptors and Ligands
|
12 |
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
|
20 |
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
|
14 |
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
|
18 |
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
|
21 |
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain
|
14 |
TRAF3 deficiency - HSE
|
3 |
TRAF3-dependent IRF activation pathway
|
14 |
TRAF6 mediated IRF7 activation
|
28 |
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling
|
14 |
TRAF6 mediated NF-kB activation
|
24 |
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
|
91 |
TRAF6-mediated induction of TAK1 complex within TLR4 complex
|
17 |
TRAIL signaling
|
8 |
TRIF(TICAM1)-mediated TLR4 signaling
|
98 |
TRIF-mediated programmed cell death
|
9 |
TRKA activation by NGF
|
3 |
TRP channels
|
28 |
TWIK related potassium channel (TREK)
|
3 |
TWIK-related alkaline pH activated K+ channel (TALK)
|
2 |
TWIK-related spinal cord K+ channel (TRESK)
|
1 |
TWIK-releated acid-sensitive K+ channel (TASK)
|
2 |
TYSND1 cleaves peroxisomal proteins
|
7 |
Tachykinin receptors bind tachykinins
|
5 |
Tandem of pore domain in a weak inwardly rectifying K+ channels (TWIK)
|
3 |
Tandem pore domain halothane-inhibited K+ channel (THIK)
|
1 |
Tandem pore domain potassium channels
|
12 |
Tat-mediated HIV elongation arrest and recovery
|
35 |
Tat-mediated elongation of the HIV-1 transcript
|
47 |
Telomere C-strand (Lagging Strand) Synthesis
|
24 |
Telomere C-strand synthesis initiation
|
8 |
Telomere Extension By Telomerase
|
6 |
Telomere Maintenance
|
63 |
Terminal pathway of complement
|
8 |
Termination of O-glycan biosynthesis
|
26 |
Termination of translesion DNA synthesis
|
32 |
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
|
10 |
The AIM2 inflammasome
|
3 |
The IPAF inflammasome
|
5 |
The NLRP1 inflammasome
|
3 |
The NLRP3 inflammasome
|
16 |
The activation of arylsulfatases
|
13 |
The canonical retinoid cycle in rods (twilight vision)
|
23 |
The citric acid (TCA) cycle and respiratory electron transport
|
175 |
The fatty acid cycling model
|
5 |
The phototransduction cascade
|
34 |
The proton buffering model
|
5 |
The retinoid cycle in cones (daylight vision)
|
7 |
The role of GTSE1 in G2/M progression after G2 checkpoint
|
78 |
The role of Nef in HIV-1 replication and disease pathogenesis
|
29 |
Threonine catabolism
|
5 |
Thrombin signalling through proteinase activated receptors (PARs)
|
32 |
Thromboxane signalling through TP receptor
|
23 |
Thyroxine biosynthesis
|
10 |
Tie2 Signaling
|
18 |
Tight junction interactions
|
30 |
Tolerance by Mtb to nitric oxide produced by macrophages
|
13 |
Tolerance of reactive oxygen produced by macrophages
|
11 |
Toll Like Receptor 10 (TLR10) Cascade
|
85 |
Toll Like Receptor 2 (TLR2) Cascade
|
98 |
Toll Like Receptor 3 (TLR3) Cascade
|
97 |
Toll Like Receptor 4 (TLR4) Cascade
|
129 |
Toll Like Receptor 5 (TLR5) Cascade
|
85 |
Toll Like Receptor 7/8 (TLR7/8) Cascade
|
92 |
Toll Like Receptor 9 (TLR9) Cascade
|
96 |
Toll Like Receptor TLR1:TLR2 Cascade
|
98 |
Toll Like Receptor TLR6:TLR2 Cascade
|
95 |
Toll-Like Receptors Cascades
|
155 |
Toxicity of botulinum toxin type A (BoNT/A)
|
9 |
Toxicity of botulinum toxin type B (BoNT/B)
|
8 |
Toxicity of botulinum toxin type C (BoNT/C)
|
4 |
Toxicity of botulinum toxin type D (BoNT/D)
|
6 |
Toxicity of botulinum toxin type E (BoNT/E)
|
5 |
Toxicity of botulinum toxin type F (BoNT/F)
|
6 |
Toxicity of botulinum toxin type G (BoNT/G)
|
4 |
Toxicity of tetanus toxin (TeNT)
|
2 |
Trafficking and processing of endosomal TLR
|
13 |
Trafficking of AMPA receptors
|
31 |
Trafficking of GluR2-containing AMPA receptors
|
17 |
Trafficking of myristoylated proteins to the cilium
|
5 |
Transcription from mitochondrial promoters
|
4 |
Transcription of E2F targets under negative control by DREAM complex
|
19 |
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1
|
16 |
Transcription of the HIV genome
|
74 |
Transcription-Coupled Nucleotide Excision Repair (TC-NER)
|
78 |
Transcriptional activation of cell cycle inhibitor p21
|
4 |
Transcriptional Regulation by E2F6
|
34 |
Transcriptional Regulation by TP53
|
367 |
Transcriptional activation of mitochondrial biogenesis
|
57 |
Transcriptional activation of p53 responsive genes
|
4 |
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
|
44 |
Transcriptional regulation by RUNX1
|
208 |
Transcriptional regulation by RUNX2
|
121 |
Transcriptional regulation by RUNX3
|
96 |
Transcriptional regulation by small RNAs
|
78 |
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors
|
37 |
Transcriptional regulation of pluripotent stem cells
|
36 |
Transcriptional regulation of white adipocyte differentiation
|
84 |
Transfer of LPS from LBP carrier to CD14
|
2 |
Transferrin endocytosis and recycling
|
31 |
Translation
|
294 |
Translation initiation complex formation
|
59 |
Translesion Synthesis by POLH
|
19 |
Translesion synthesis by POLI
|
17 |
Translesion synthesis by POLK
|
17 |
Translesion synthesis by REV1
|
16 |
Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template
|
39 |
Translocation of SLC2A4 (GLUT4) to the plasma membrane
|
71 |
Translocation of ZAP-70 to Immunological synapse
|
38 |
Transmission across Chemical Synapses
|
223 |
Transmission across Electrical Synapses
|
5 |
Transport and synthesis of PAPS
|
6 |
Transport of HA trimer, NA tetramer and M2 tetramer from the endoplasmic reticulum to the Golgi Apparatus
|
3 |
Transport of Mature Transcript to Cytoplasm
|
85 |
Transport of Mature mRNA Derived from an Intronless Transcript
|
44 |
Transport of Mature mRNA derived from an Intron-Containing Transcript
|
76 |
Transport of Mature mRNAs Derived from Intronless Transcripts
|
45 |
Transport of Ribonucleoproteins into the Host Nucleus
|
38 |
Transport of bile salts and organic acids, metal ions and amine compounds
|
86 |
Transport of connexins along the secretory pathway
|
3 |
Transport of connexons to the plasma membrane
|
20 |
Transport of fatty acids
|
8 |
Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus
|
9 |
Transport of glycerol from adipocytes to the liver by Aquaporins
|
2 |
Transport of inorganic cations/anions and amino acids/oligopeptides
|
107 |
Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane
|
7 |
Transport of nucleotide sugars
|
9 |
Transport of organic anions
|
12 |
Transport of small molecules
|
726 |
Transport of the SLBP Dependant Mature mRNA
|
38 |
Transport of the SLBP independent Mature mRNA
|
37 |
Transport of vitamins, nucleosides, and related molecules
|
39 |
Transport to the Golgi and subsequent modification
|
185 |
Triglyceride biosynthesis
|
14 |
Triglyceride catabolism
|
24 |
Triglyceride metabolism
|
38 |
Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA
|
17 |
Truncations of AMER1 destabilize the destruction complex
|
14 |
Tryptophan catabolism
|
14 |
Type I hemidesmosome assembly
|
11 |
Type II Na+/Pi cotransporters
|
3 |
UCH proteinases
|
96 |
UNC93B1 deficiency - HSE
|
2 |
Ub-specific processing proteases
|
205 |
Ubiquinol biosynthesis
|
8 |
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
|
53 |
Ubiquitin-dependent degradation of Cyclin D
|
52 |
Ubiquitin-dependent degradation of Cyclin D1
|
52 |
Unblocking of NMDA receptor, glutamate binding and activation
|
17 |
Uncoating of the HIV Virion
|
8 |
Uncoating of the Influenza Virion
|
9 |
Unfolded Protein Response (UPR)
|
95 |
Unwinding of DNA
|
12 |
Uptake and actions of bacterial toxins
|
48 |
Uptake and function of anthrax toxins
|
16 |
Uptake and function of diphtheria toxin
|
7 |
Urea cycle
|
10 |
Utilization of Ketone Bodies
|
4 |
VEGF binds to VEGFR leading to receptor dimerization
|
8 |
VEGF ligand-receptor interactions
|
8 |
VEGFA-VEGFR2 Pathway
|
97 |
VEGFR2 mediated cell proliferation
|
19 |
VEGFR2 mediated vascular permeability
|
27 |
VLDL assembly
|
5 |
VLDL clearance
|
6 |
VLDLR internalisation and degradation
|
12 |
Variant SLC6A14 may confer susceptibility towards obesity
|
1 |
Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG)
|
1 |
Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG)
|
1 |
Vasopressin regulates renal water homeostasis via Aquaporins
|
44 |
Vasopressin-like receptors
|
6 |
Vesicle-mediated transport
|
756 |
Vif-mediated degradation of APOBEC3G
|
56 |
Viral Messenger RNA Synthesis
|
50 |
Viral RNP Complexes in the Host Cell Nucleus
|
7 |
Viral mRNA Translation
|
101 |
Virus Assembly and Release
|
11 |
Visual phototransduction
|
100 |
Vitamin B1 (thiamin) metabolism
|
5 |
Vitamin B2 (riboflavin) metabolism
|
7 |
Vitamin B5 (pantothenate) metabolism
|
17 |
Vitamin C (ascorbate) metabolism
|
8 |
Vitamin D (calciferol) metabolism
|
11 |
Vitamin E
|
1 |
Vitamins
|
6 |
Vitamins B6 activation to pyridoxal phosphate
|
3 |
Voltage gated Potassium channels
|
43 |
Vpr-mediated induction of apoptosis by mitochondrial outer membrane permeabilization
|
4 |
Vpr-mediated nuclear import of PICs
|
42 |
Vpu mediated degradation of CD4
|
53 |
VxPx cargo-targeting to cilium
|
21 |
WNT ligand biogenesis and trafficking
|
26 |
WNT ligand secretion is abrogated by the PORCN inhibitor LGK974
|
1 |
WNT mediated activation of DVL
|
8 |
WNT5A-dependent internalization of FZD2, FZD5 and ROR2
|
13 |
WNT5A-dependent internalization of FZD4
|
15 |
Wax biosynthesis
|
4 |
XAV939 inhibits tankyrase, stabilizing AXIN
|
2 |
XBP1(S) activates chaperone genes
|
55 |
Xenobiotics
|
23 |
YAP1- and WWTR1 (TAZ)-stimulated gene expression
|
16 |
ZBP1(DAI) mediated induction of type I IFNs
|
21 |
Zinc efflux and compartmentalization by the SLC30 family
|
7 |
Zinc influx into cells by the SLC39 gene family
|
10 |
Zinc transporters
|
17 |
activated TAK1 mediates p38 MAPK activation
|
23 |
alpha-linolenic (omega3) and linoleic (omega6) acid metabolism
|
13 |
alpha-linolenic acid (ALA) metabolism
|
13 |
betaKlotho-mediated ligand binding
|
3 |
c-src mediated regulation of Cx43 function and closure of gap junctions
|
3 |
cGMP effects
|
18 |
cRNA Synthesis
|
4 |
eNOS activation
|
11 |
eNOS activation and regulation
|
15 |
mRNA 3'-end processing
|
57 |
mRNA Capping
|
29 |
mRNA Editing
|
10 |
mRNA Editing: A to I Conversion
|
2 |
mRNA Editing: C to U Conversion
|
8 |
mRNA Splicing
|
188 |
mRNA Splicing - Major Pathway
|
180 |
mRNA Splicing - Minor Pathway
|
52 |
mRNA decay by 3' to 5' exoribonuclease
|
16 |
mRNA decay by 5' to 3' exoribonuclease
|
15 |
mTOR signalling
|
40 |
mTORC1-mediated signalling
|
23 |
mitochondrial fatty acid beta-oxidation of saturated fatty acids
|
11 |
mitochondrial fatty acid beta-oxidation of unsaturated fatty acids
|
6 |
p130Cas linkage to MAPK signaling for integrins
|
15 |
p38MAPK events
|
13 |
p53-Dependent G1 DNA Damage Response
|
66 |
p53-Dependent G1/S DNA damage checkpoint
|
66 |
p53-Independent DNA Damage Response
|
53 |
p53-Independent G1/S DNA damage checkpoint
|
53 |
p75 NTR receptor-mediated signalling
|
99 |
p75NTR negatively regulates cell cycle via SC1
|
6 |
p75NTR recruits signalling complexes
|
14 |
p75NTR regulates axonogenesis
|
10 |
p75NTR signals via NF-kB
|
17 |
phospho-PLA2 pathway
|
2 |
phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
|
15 |
rRNA modification in the mitochondrion
|
6 |
rRNA modification in the nucleus and cytosol
|
60 |
rRNA processing
|
203 |
rRNA processing in the mitochondrion
|
10 |
rRNA processing in the nucleus and cytosol
|
193 |
snRNP Assembly
|
55 |
t(4;14) translocations of FGFR3
|
1 |
tRNA Aminoacylation
|
42 |
tRNA modification in the mitochondrion
|
9 |
tRNA modification in the nucleus and cytosol
|
43 |
tRNA processing
|
111 |
tRNA processing in the mitochondrion
|
5 |
tRNA processing in the nucleus
|
60 |
trans-Golgi Network Vesicle Budding
|
74 |
truncated APC mutants destabilize the destruction complex
|
14 |
vRNA Synthesis
|
4 |
vRNP Assembly
|
6 |
via Death Receptors in the presence of ligand
|
19 |
via Dependence Receptors in the absence of ligand
|
10 |